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Abstract 
It is estimated that 1.3 billion people worldwide are either overweight or obese, making this a 
global epidemic. An effective weight-loss method involves the lifestyle changes of increased 
physical activity and lowered energy intake. These changes are difficult to carry out and to 
maintain. As a result, there is a soaring demand for weight-loss aids, including dietary 
supplements, which exploit consumers’ eagerness to find an effortless weight-loss solution. 
These supplements are easily accessible, require no prescription and are heavily marketed to 
suggest that weight loss is achievable without exercise and dieting. One such dietary 
supplement, Bioslim, is tested in this study. 
The aim of this study was to investigate whether Bioslim results in greater weight loss than a 
placebo, and whether the marketing of the Bioslim brand has an influence on the placebo 
response. 
Overweight adults residing in Cape Town (n = 87) were recruited by advertising in 
community newspapers and setting up stands at shopping centres. The subjects were 
randomised into one of four groups: Bioslim in Bioslim packaging (n = 26), Bioslim in 
unbranded packaging (n = 22), placebo in Bioslim packaging (n = 17) and placebo in 
unbranded packaging (n = 22). At baseline, the subjects were given one of the four products 
and anthropometric measurements (weight, height and skinfold thickness) were taken. After 
four weeks, these measurements were repeated. The subjects also had to complete a 
questionnaire regarding their experiences. 
The body mass index (BMI) for the total population was 31.90 kg/m
2 
(SD = 3.91) at baseline 
and 31.89 kg/m
2
 (SD = 3.92) at follow-up. None of the measured anthropometric variables 
had changed significantly after four weeks. When the total study group sample was analysed, 
based on the allocated drug treatment groups (active or placebo), neither group showed 
significant weight loss from baseline to follow-up. 
Twenty-three subjects from the Bioslim group and 21 from the unbranded group reported 
exercising during the trial. The total group’s exercise time correlated significantly with fat-
mass reduction (r = -0.31, p = 0.004). Furthermore, when data was analysed separately for the 
active and placebo groups, the active group showed a significant correlation (r = -0.45, p = 
0.0012), while the placebo group showed an insignificant correlation (r = -0.05, p = 0.77). 
The same was not reflected in weight loss (r = -0.007, p = 0.95). 
Stellenbosch University http://scholar.sun.ac.za
iii 
 
It is concluded that Bioslim is an ineffective weight-loss supplement: subjects receiving 
active pills evidenced no significant beneficial changes in weight, waist circumference or 
body composition. More than half of the subjects attempted dieting and exercising, but these 
efforts were insufficient to impact on weight loss. The marketing and packaging of Bioslim 
did not enhance the placebo effect. 
One subject from the active group withdrew from the study, complaining of severe headaches 
and heart palpitations. There was no difference in adverse events reported by the remaining 
active and placebo group subjects. 
In conclusion, this study emphasises the need for better regulation of the efficacy and safety 
of dietary supplements. 
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Opsomming 
Daar word geskat dat 1.3 biljoen mense wêreldwyd oorgewig of vetsugtig is, wat dit ‘n 
globale problem maak. ‘n Effektiewe gewigsverlies metode inkorporeer leefstyl veranderinge 
soos verhoogde fisiese aktiwiteit en ‘n laer energie inname. Hierdie veranderinge is moeilik 
om uit te voer en vol te hou. Die gevolg is ‘n stygende aanvraag vir gewigsverliesprodukte en 
supplemente, wat verbruikers se gretigheid om ‘n maklike gewigsverlies oplossing te kry, 
uitbuit.  Hierdie supplemente is maklik verkrygbaar sonder ‘n voorskrif en word aggressief 
bemark met bewering dat gewigsverlies moontlik is sonder oefening en dieetaanpassing.  Een 
van die beskikbare produkte, Bioslim, is getoets in die studie. 
Die doel van die studie was om te ondersoek of die gewigsverlies produk, Bioslim, lei tot ‘n 
groter gewigsverlies as ‘n plasebo produk en of die bemarking van die Bioslim handelsmerk 
‘n invloed op die plasebo-effek het.    
Oorgewig volwassenes woonagtig in Kaapstad (n = 87) is gewerf deur advertering in 
gemeenskapskoerante en deur stalletjies by inkopiesentrums.  Die proefpersone is ewekansig 
in vier groepe ingedeel: Bioslim in Bioslim verpakking (n = 26); Bioslim in verpakking 
sonder ‘n handelsmerk (n = 22); ‘n plasebo produk in Bioslim verpakking (n = 17) en ‘n 
plasebo produk in verpakking sonder ‘n handelsmerk (n = 17).  Met aanvang van die studie is 
een van die vier produkte aan die proefpersone gegee en antropometriese metings (gewig, 
lengte en velvoudikte) is gemeet. Metings is na vier weke herhaal. Die proefpersone moes 
ook ‘n vraelys oor hul ervarings voltooi. 
Die liggaamsmassa indeks (LMI) van die totale populasie was 31,90 kg/m
2 
(SD = 3.91) by 
basislyn en 31.89 kg/m
2
 (SD = 3.92) met opvolg.  Geen van die antropometriese 
veranderlikes het betekenisvol verander na vier weke nie. Met ontleding van die totale studie 
polulasie, gebasseer op die toegekende behandeling (aktiewe of plasebo bestanddele), is 
gevind dat geen groep ‘n betekenisvolle gewigsverlies getoon het van basislyn tot opvolg nie.  
Drie-en-twintig proefpersone uit die Bioslim groep en 21 uit die geen-handelsmerk-groep het 
gerapporteer dat hul geoefen het gedurende die studie.  Die totale groep se oefenings tydsduur 
het betekenisvol gekorreleer met ‘n verlaging in vetmassa (r = -0.31, p = 0.004). Met verdere 
analiese van die data in die aktiewe en plasebo groepe, is gevind dat die aktiewe groep ‘n 
betekenisvolle korrelasie getoon het (r = -0.45, p = 0.0012), maar die plasebo groep nie (r = -
0.05, p = 0.77). Hierdie bevinding is nie gevind in die gewigsverlies nie (r = -0.007, p = 0.95). 
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Die gevolgtrekking word gemaak dat Bioslim ‘n oneffektiewe gewigsverlies supplement is, 
aangesien proefpersone wat die aktiewe pille geneem het, geen betekenisvolle voordelige 
veranderinge in hul gewig, middelomtrek of liggaamsamestelling getoon het nie. Alhoewel ‘n 
betekenisvolle korrelasie gevind is tussen oefeningsduur en verlies aan vetmassa in meer as 
die helfte van die proefpersone, was die omvang daarvan onvoldoende om ‘n impak op hul 
gewigsverlies te hê. Die bemarking en Bioslim handelsmerk het nie die placebo-effek 
versterk nie.  
Een persoon uit die aktiewe groep het van die studie onttrek as gevolg van erge hoofpyn en 
hartkloppings. Daar was geen verskil in die nadelige effekte gerapporteer deur die 
oorblywende proefpersone in die aktiewe en plasebo groepe nie. 
Ten slotte beklemtoon die studie die behoefte aan beter regulering van die effektiwiteit en 
veiligheid van dieetsupplemente. 
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Chapter 1 
Literature Overview 
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1.1 Overweight and obesity 
1.1.1 An overview of overweight and obesity 
According to the World Health Organisation’s (WHO) classification, an individual is 
overweight if their body mass index (BMI) is greater than or equal to 25kg/m
2
. If it is greater 
than or equal to 30kg/m
2
, they are classified as obese
 1
. Physiologically, an individual 
becomes overweight when the energy expended is less than the energy consumed. The excess 
energy is then stored as triglycerides in the adipose tissue and weight is gained
 2
. However, 
overweight and obesity is a complex issue, influenced by multiple factors such as culture, 
behaviour, environment, genetics and metabolism
 3
. 
It is estimated that 1.3 billion people worldwide are either overweight or obese, which makes 
it a global epidemic
 4
. The greatest prevalence of overweight and obese individuals is found in 
developed countries such as the United States (where 65% of adults are either overweight or 
obese, according to the 1999-2002 National Health and Nutrition Examination Survey result
 
5
). However, it is also a major concern in developing countries. 
In South Africa, the problem is amplified by the double burden of under-nutrition and chronic 
diseases of lifestyle. The overall prevalence of overweight and obesity is relatively high 
compared to other African countries, with more than 29.9% of men and 55% of women in 
South Africa being classified as overweight or obese
 6
. Indian women have the highest 
prevalence of overweight and obesity (59.2%), with slightly lower levels among Black 
African women (56.2%), Coloured women (52.2%) and White women (38%). Among males, 
White men have the highest prevalence (48%), followed by Indian men (45%), men of mixed 
ancestry (36%) and lastly, Black men (27%). Besides ethnicity, such high prevalence is also 
associated with age, low level of education and degree of urbanisation
 6
. 
The phenomenon of the double burden is also seen from the 2005 NFCS (National Food 
Consumption Survey) data
 7
. The cross-sectional survey showed that 5.04% of children 
between the ages of 1-9 years were obese and 17.12% were overweight. A significant 
difference in prevalence was found between rural and urban areas, as well as between age 
groups. The highest prevalence was found in urban areas and in children between the ages of 
1-3 years. These data indicate that nutrition transition is taking place in the urban areas and 
that under-nutrition, which is associated with infectious diseases, is not the only concern for 
children any longer. Furthermore, the prevalence of stunting (19.3%) is similar to the 
combined prevalence of overweight and obesity (22.16%) of children between the ages of 1-8 
years old in SA. Additionally, stunted children are predisposed to become overweight adults 
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when adequate nutrition is available, which further increases the risk of children becoming 
obese adults
 7
. 
 
A follow-up survey, conducted in 2005, found that on a national level, 10% of children aged 
1-9 years were overweight and 4% were obese. Stunting and underweight still remains the 
most common of nutritional disorders, since 20% of the children are stunted and 10% are 
classified as underweight
 8
. 
 
The most recent national data indicate that the combined national prevalence of overweight 
and obesity among women is 51.5% with the highest provincial prevalence in the Western 
Cape (58.7%)
 8
.
 
1.1.2 Consequences of overweight and obesity 
1.1.2.1 The effect of overweight and obesity on physical health 
Obesity is listed by the WHO as one of the ten leading risk factors for mortality
 9
. There is a 
general consensus that obesity (BMI > 30), as well as overweight (BMI> 24.9), increases the 
risk of a number of major chronic diseases or conditions including insulin resistance, 
hyperlipidaemia, hypertension and stroke, type 2 diabetes, and cardiovascular disease, as well 
as cancers of some sites
 4
. 
Globally, non-communicable diseases caused an estimated 35 million deaths in 2005 which 
represents 60% of all deaths. Eighty per cent of these deaths occur in low- and middle-income 
communities and it has been predicted that deaths from non-communicable diseases will 
increase by a further 17% over the next 10 years. Furthermore, the rapidly increasing 
incidence of these diseases is affecting poor and disadvantaged populations 
disproportionately, causing enormous human suffering and threatening the economies of 
many countries, as they impact on the older and experienced members of the workforce
 4
. 
1.1.2.2 Heart diseases 
Overweight and obesity increase the risk of developing coronary heart disease (CHD), where 
excess weight increases various cardiovascular risk factors such as hypertension, high blood-
lipid concentrations and type 2 diabetes mellitus. CHD is reported to have a linear 
relationship with BMI, and from the Framingham study it is estimated that a 10% loss of 
weight can reduce the risk of CHD by 20%
 10
. 
Obese individuals invest more effort in breathing due to the excess weight on the chest, which 
requires the heart to work harder in order to pump adequate amounts of blood into the lungs 
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and throughout the body for good perfusion. It is also common to find left ventricular 
hypertrophy in obese individuals as the left chamber of the heart is responsible for the 
pumping of blood throughout the body. Eventually this can lead to heart failure and a heart 
transplant would be required
 10
. 
Not only is the heart working harder to cope with the excess body weight, but a high fat 
dietary intake can also result in a poor lipid profile. Elevated levels of cholesterol and lipids 
in the blood can easily cause plaque and the narrowing of the blood vessels. This may 
eventually lead to a number of vascular complications where the supply of blood and oxygen 
is restricted due to a blocked artery. These vascular complications include ischemic heart 
disease such as myocardial infarction, or cerebrovascular incidents in which the blood supply 
to the brain is hindered due to a burst vessel. Both of these complications have a high 
mortality rate, and heart disease is currently the leading cause of death in the western world 
with stroke coming third in the ranking, responsible for 10% of deaths worldwide each year
 
11
. According to the World Health report by the WHO, cardiovascular disease accounts for 
9.2% of all deaths in African countries. In South Africa, specifically, 195 people die from 
cardiovascular diseases (CVD) every day
 12
. 
1.1.2.3 Type 2 diabetes mellitus 
An increase in weight is strongly associated with the risk of developing type 2 diabetes 
mellitus, as it is related to excess intake of calories and insulin resistance. Constant high 
levels of blood glucose require additional insulin to be produced by the pancreas. Over time, 
this desensitizes the cells to the constant high insulin levels and individuals may become pre-
diabetic. Eventually, with the continuing death of beta cells, the pancreas can no longer 
produce the required amount of insulin to stabilize postprandial hyperglycaemia to normal 
blood glucose levels
 10
. 
This is further verified by a prospective study by Hu et al.
 10
, which showed that overweight 
and obesity was the most important predictor of diabetes. 91% of the subjects who developed 
diabetes during the study period can attribute it to poor diet and lack of exercise. From a 
meta-analysis study, it has been shown that the incidence rate ratio (IRR) for obese men was 
6.74 and for obese women was 12.41 (BMC public health). It was estimated in 2000 that 1.5 
million South Africans are diabetic and that 3% of men and 6% of women over the age of 30 
die from diabetic-related complications
 12
. 
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1.1.2.4 Gallstones 
An increased risk of developing gallstones is associated with an increase in weight. It was 
found that the risk increased by nearly 7 times when comparing normal weight women to 
obese women
 13
. 
1.1.2.5 Osteoarthritis 
Epidemiological studies have shown that as BMI increases, so does the prevalence of knee 
and finger osteoarthritis. The increase in prevalence cannot be solely attributed to the 
additional stress brought on by excess weight; metabolic disturbances of the cartilage that are 
associated with obesity also play a role. This view is supported by the evidence that 
osteoarthritis of the finger, which is not impacted by mechanical stress, also occurs more 
frequently in obese individuals. Additionally, a drop of BMI by 2 units can reduce the risk of 
osteoarthritis by more than 50%
 14
. 
1.1.2.6 Cancer 
Various prospective and retrospective studies have also shown that obesity and overweight 
are strongly associated with cancer of the colon, rectum, breast, ovaries and endometrium
 15
. 
For colon cancer, the risk profile for men and women is similar, as for both; an increase in 
BMI is related to an increased risk of colon cancer. A high waist-to-hip ratio specifically, is a 
strong independent predictor
 16
. 
 
From the epidemiologic studies, it is suggested that obesity correlates strongly to breast 
cancer, specifically in postmenopausal women who are not receiving hormone replacement 
therapy. In postmenopausal women, the peripheral fat produces oestrogen and the higher the 
level of oestrogen production, the greater the risk of breast cancer. It has been shown that the 
breast cancer incidence rate ratio for overweight women is 1.13 and increases to 1.3 for obese 
women
 16
. 
1.1.2.7 Women’s reproductive health 
Premenopausal obese women may experience an irregular menstrual cycle or amenorrhea and 
this in turn can lead to infertility. From the Nurse’s Health Study, it was found that the greater 
the BMI at the age of 18 years, the greater the risk of ovulatory infertility
 17, 18
. 
 
During pregnancy, higher pregnancy weight is associated with higher incidences of late foetal 
death and gestational diabetes, which can result in complications during delivery. In obese 
pregnant women, the prevalence of hypertension increases by 10 times and there is a 10% 
increase in the risk of developing diabetes
 17, 18
. 
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Seven overweight and obesity related co-morbidities have been summarised in Table 1. 
 
Table 1: Physical morbidities that are related to overweight and obesity 
Health Problems Relative risk 
Hypertension  
It is threefold more likely for overweight and obese adults 
(between the ages of 20-75) to develop hypertension than normal 
weight individuals
 19
.  
Hypercholesterolemia 
(>6.7mmol/L) 
1.5 times higher risk in obese individuals than lean counterparts
 
20
.  
Diabetes Mellitus  
Adults with a BMI of 40 or higher are 7.37 times more likely to 
develop diabetes than adults with normal weight
 10
. 
Gallbladder disease 
Gallstones are 4 times more likely to be found in obese than 
normal weight individuals
 21
. 
Gout 
2.6 times more likely for obese individuals compared to normal 
weight individuals
 22
. 
Cancer 
For individuals who are 40% or more overweight, there is an 
increased risk of cancer: 1.33 times in men and 1.55 times in 
women
 16
. 
Specific cancers related to obesity in men include prostate, 
stomach, oesophagus, liver, rectum and colorectal cancers. For 
women, the list includes gallbladder, uterus, kidney, colon, 
rectum, gallbladder, liver, cervical, ovarian and breast cancer
 15
.
 
Sleep disorder breathing 
(including sleep apnoea)  
 Obese adults are 10 times more likely to develop sleep apnoea
 23
. 
 
1.1.2.8 The cost of overweight and obesity 
In addition to the increased risk of co-morbidities, overweight and obesity place a heavy 
burden on healthcare systems at both government level and in the private sector. The United 
States’ direct cost for treating obesity-related illness has been estimated at $51.6 billion per 
year, which equates to 6-7% of the country’s National Health Expenditure. The money spent 
specifically on weight reduction amounts to well over $30 billion
 24
. One study indicated that 
the number of medically diagnosed illnesses and the need for healthcare resources increased 
as BMI increased
 25
. Another study analysed the employees of 298 companies (n = 8822); the 
obese subjects from this study generated a significantly higher healthcare cost compared to 
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their non-obese colleagues when adjusted for age, sex and chronic health conditions
 26
. As 
previously mentioned, one of the common morbidities related to overweight and obesity is 
cardiovascular disease; the direct cost of CVD in South Africa is between R4.1 - R5 billion or 
roughly 25% of all healthcare expenditure. An increasing number of the work-force 
population aged 35-64 years is lost to CVD, which has a serious impact on the country’s 
economy
 27
. 
1.1.2.9 The psychological effect of overweight and obesity on an individual’s self-esteem 
and self-image 
It has been well established by various studies
 28
 that women’s perception of their body image 
has been profoundly influenced by Western culture via the media’s constant contention that 
the ideal body shape is slender
 29
. Success and happiness are associated with slender women 
and conversely, being overweight is stigmatised as lazy, unattractive, unsuccessful and 
physically unhealthy
 30
. According to Callaghan
 31
, Self-esteem is greatly affected if one learns 
to value oneself through the eyes and values of society. Hence, as an overweight individual in 
the Western culture, it is easy to internalise these negative opinions from the media and to 
develop a poor body image perception, and as a result, lower one’s self-esteem. It intensifies 
the urgency to work hard on weight-loss and to try a variety of methods to lose weight in 
order to achieve the acceptance of society, and to improve self-esteem by dissociating oneself 
from the negative connotations of being overweight.  Such body image dissatisfaction may 
not be satisfied by weight loss attempts, however, as the goal is often unrealistic. This is 
partly due to the media’s promotion of very skinny-looking women and partly due to 
advertisers promoting the false belief that it is easy to reach these goals. The unrealistic goals 
may only lead to unsuccessful weight loss attempts and intensify the sense of failure, 
increasing the frustration of obese individuals and further impairing their self-esteem. 
A high incidence of eating disorders provides further indication of the increased pressure 
from society to push individuals into being slender
 32
. 
However, in black communities, the incidence of eating disorders was previously considered 
rare, as the cultural perception of overweight was related to affluence, health and, for women, 
fertility
 33
. Overweight black women are resistant to weight-loss and adopting healthy lifestyle 
behaviours as weight-loss is associated with HIV/AIDS and wasting syndrome
 34
. This 
cultural perception is gradually diminishing as westernisation of the community takes place. 
Black females are now adapting to the new perceived ideal body shape, and the same pressure 
from society to be slender is being applied
 35
. According to Freud
 36
, body image is the 
individual’s subjective sense of the body and is theorized to be a core component of 
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personality. In addition, Fisher
 35
 states that body image is a result of socio-cultural values and 
social responses to body appearance and a continuous body-related experience. These self-
images are established at a young impressionable age and media can have a profound effect 
on them. It was found that obesity in children is the most stigmatised and the least socially 
acceptable condition
 37
. As a study
 37
 has shown, normal weight children ranked obese 
children as the least desirable friends, as they are perceived as lazy, dirty and unintelligent. 
These descriptions are from children as young as 6 years old. As a result, obese children feel 
excluded from social activities and easily become targets for teasing. Consequently, obese 
children are often found to have a lower self-esteem and tend to miss school four times more 
often than normal weight children, leading often to poor performance in school
 38
. 
These social influences during childhood have a lifelong effect on the individual, as it has 
been found that obese children who grow up as obese adults, tend to have a lower education 
level, less income and are less likely to be married
 37
. 
Being overweight has psychological as well as physiological effects. Overweight and obese 
individuals are discriminated against in work, social and healthcare settings
 26
. Studies that 
investigated workplace prejudice showed that participants hold negative stereotypes of 
overweight individuals, including a lack of self-discipline, a poor professional appearance and 
low supervisory potential
 39
.  Similar results were found in a medical setting
 40
. 
 
Results from a study of general practitioners, using anonymous questionnaires, reported that 
66% thought their obese patients lacked self-control and 39% thought they were lazy. This is 
worrisome; while physicians recognise the health implications of obesity, few of them discuss 
the importance of weight management with their overweight patients
 40
. Salinas et al.
 41
 
reported that although physicians believed obesity can be managed successfully, they do not 
feel confident in their ability to do so. Only physicians who have greater knowledge, a 
positive attitude and more time available to spend on weight management, would consider 
providing counselling to their obese patients. This lack of medical support further exacerbates 
the problem of overweight and obesity by forcing patients to use non-substantiated and often 
inappropriate commercial assistance
 41
. 
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1.2. Overview of treatment options for overweight and obesity 
Due to the alarmingly high prevalence of overweight and obesity, a search for a treatment that 
is effective, sustainable and with acceptable side effects is essential. There are several 
treatment options available for weight loss and the decision regarding which treatment option 
to use should be based on the individual’s degree of overweight and weight-loss history. 
1.2.1 Lifestyle intervention for obesity 
This is the most cost-effective intervention, but one that requires the most effort from the 
individual, as this intervention includes a restricted energy diet and exercise. Table 2 displays 
7 trials that have studied the effectiveness of lifestyle interventions over 1.5 years and how 
sustainable they were in order for subjects to maintain their weight loss. It was found that in 
all 7 trials the treatment group lost significantly more weight than the placebo group. All trials 
included a follow-up meeting after treatment had been completed, where physicians kept 
regular contact with the subjects to provide support. These follow-up meetings were found to 
be the pivotal factor in the maintenance or the continuation of the weight loss. On average, 
60-80% of the weight loss could be maintained with bi-monthly contact after the treatment 
phase
 42
.This treatment option for overweight and obesity is one with minimal risk and side 
effects, though it does require commitment from subjects for the success of the intervention. 
It is something that is often considered a formidable task. 
Table 2: Randomised trials that investigate the effectiveness of lifestyle intervention
 42 
Research group 
p - value Total 
sample size 
Follow-up 
period (years) 
Weight change at the 
end of the trial (kg) 
    Treatment  Placebo  
Diabetes prevention 
program
 43
 
p < 0.01 3224  
 
2.8 -5.6 -0.2 
Finnish Diabetes 
 Prevention
 44
  
p < 0.01 522 
 
3.2 -3.5 -0.8 
TONE
 45
  
p < 0.01 585 
 
2.5 -4.7 -0.9 
Da Qing IGT Study
 46
  
p < 0.05 332 
 
6.0 -1.8 0.3 
Hypertension Control 
Program
 47
 
p < 0.01 189 
 
4.0 -1.8 2 
MRFIT
 48
  
1
 p < 0.01 12866 6-8 -0.5 0.3 
                                                     
1
 Multiple Risk Factor Intervention for the Prevention of Coronary Heart Disease 
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1.2.2 Behavioural therapy for obesity 
Behavioural therapy coaches individuals to develop a set of skills for healthy eating. 
Behavioural therapy is based on classical conditioning where eating is assumed to be 
prompted by cues which are linked to food. Hence, weight loss can be promoted by helping 
subjects to develop new responses when facing triggers relating to eating
 49
. 
Short-term results have shown that subjects had a mean weight loss of 9.6kg after 21 weeks 
of therapy
 50
, and similar results were found in other studies
 51, 52, 53
. 
Behavioural therapy is often combined with other treatment options such as pharmacotherapy. 
Wadden et al.
 54
 have shown that pharmacotherapy with behavioural therapy resulted in the 
most weight lost (17.7% of baseline weight) when compared to groups that received only 
weight-loss drugs or behavioural therapy. The combined treatment group also maintained 
most of the weight loss at 1 year. Results from a systematic review showed that behaviour 
therapy coupled with Sibutramine led to weight loss that was maintained for up to 18 months
 
55
. 
1.2.3 Bariatric surgery for obesity 
Bariatric surgery includes procedures such as gastric banding, gastric bypass and duodenal 
switch, and is indicated for individuals who are morbidly obese with the BMI > 40 or  35 
with co-morbidity according to NIH (National Institute of Health)
 56
. According to a 
systematic review and meta-analysis study, bariatric surgery can markedly reduce co-
morbidities such as type 2 diabetes, hypertension and hyperlipidaemia post-surgery
 57
. 
However, adverse effects after surgery are common with 7 - 8% of the patients suffering from 
severe side-effects such as sub-phrenic abscess, pneumonia and wound infection. The 
mortality rate for such surgery is considered low, between 0.5 - 1%
 42
. 
Bariatric surgery is an effective weight loss intervention, although one needs to consider the 
cost-effectiveness of the surgery and regard it as the last option when all other non-surgical 
interventions have been attempted, and have failed. 
1.2.4 Pharmacotherapy for weight loss 
According to the FDA’s estimation, 50 million Americans go on diet each year by joining 
weight-loss programmes or making use of weight-loss drugs, but only 5% maintain the lost 
weight, if any weight was lost to begin with
 58
. Pharmacotherapy is one of the most popular 
choices of treatment for overweight and obesity as it requires the least amount of effort from 
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individuals. Although an effective and safe weight-loss drug is highly desirable, there is not 
one currently available without undesirable side effects and careful consideration is therefore 
required before the commencement of this treatment option. The drug’s benefits regarding 
weight loss must be weighed up against its side effects and correct usage of such drugs must 
be ensured to avoid abuse. Anti-obesity drugs are available to the public in two ways: as 
prescribed medication and as an over-the-counter dietary supplement. The benefit of 
prescribed medication is that drugs are tested for efficacy and possible side effects via 
scientifically sound clinical trials. (Table 3 is a summary of the clinical trial criteria used 
when conducting a drug efficacy and safety trial.) However the same does not necessarily 
apply to over-the-counter dietary supplements. 
Table 3: Criteria for anti-obesity drugs to ensure efficacy according to the Food Drug 
Administration (FDA) and Committee for Propriety Medicinal Products (CPMP)
 59 
 FDA criteria CPMP 
Initial trial 
Type of trial  
Randomised, double blinded, placebo-controlled 
dose ranging: for identification of the lowest 
effective dose 
Not specified  
 
Duration  
 
3 - 6 months  
Not specified 
Subject type  BMI >30 kg/m
2
  
End result  
Weight loss is significantly greater in the 
treatment group than placebo group 
Weight that was lost is mostly fat 
mass 
Long-term trial 
Type of trial 
Randomised, double blinded, placebo-controlled 
dose ranging: for identification of the lowest 
effective dose 
12 months, open label or random 
24 weeks for efficacy and safety  
Duration 2 years Minimum 1 year 
Subject type  
BMI >30 kg/m
2 
otherwise healthy 
Or 
BMI >27 kg/m
2 
with co-morbidities  
BMI >30 kg/m
2
 otherwise healthy 
Or 
BMI >27 kg/m
2 
with co-
morbidities 
 
End Result  
Weight loss is significantly greater than placebo. 
At 12 months, it should be higher than 5% when 
compared to placebo group. Such weight loss is 
maintained.  
Loss of 10% of the baseline 
weight and significantly greater 
than placebo group at 12 months.  
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1.2.4.1 Prescription drugs 
Prescription weight-loss drugs require careful selection for individuals, for whom the 
treatment is appropriate, in order to avoid abuse. Such individuals should have a BMI > 
30kg/m
2
, or have a BMI of 27kg/m
2
 and also suffer from other weight-related co-morbidities 
such as dyslipidaemia, hypertension, sleep apnoea or diabetes. Individuals are often required 
to use these drugs as a long-term therapy and they are treated like any other chronic disease 
drugs, such as lipid-lowering or anti-hypertensive medication. One should aim for a loss of 
15% of the original weight after three to six months on the prescribed medication
 60
. 
Weight-loss drugs can be grouped in three main categories: 1) reducing food intake, 2) 
altering the metabolism of macronutrients and 3) increasing energy expenditure. Examples of 
drugs that have been approved by the FDA for reduction of food intake are Phentermine, 
Mazindol and Sibutramine. Orlistat has been approved for inhibiting the absorption of 
gastrointestinal lipase, which is essential for the breakdown of triglycerides to free fatty acid 
hence preventing fat absorption. There are currently no FDA-approved weight-loss drugs to 
increase energy expenditure. Ephedrine has been banned for weight-loss purposes, due to its 
dangerous side effects, although some studies have shown that it is effective when used 
together with caffeine to stimulate thermogenesis
 61
. See Table 4 for the list of FDA approved 
drugs, together with the results of their efficacy from a systematic review. 
Table 4: List of drugs approved by the FDA for weight-loss purposes
 62, 63
. 
Generic 
Name 
Trade 
Name 
Efficacy 
Notes: adverse effects, original purpose, 
drawbacks 
Approved for long-term treatment 
Orlistat Xenical 
Treatment group 
lost 2.9kg, 2.9% 
(significantly 
more) than 
placebo group. 
Possible gastrointestinal (GIT) side effects. 
Results from systematic review showed that 
80% of participants experienced GIT side effects 
such as faecal urgency, oily stool and oily 
spotting. 
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Sibutramine 
Meridial, 
Reductil 
Treatment group 
lost 4.2 kg, 
4.3% 
(significantly 
more) than 
placebo group. 
Raises blood pressure: systolic blood pressure by 
1.7 mm Hg and diastolic blood pressure by 2.4 
mm Hg. May not be appropriate for subjects 
with hypertension. 
Other side effects: Nausea, dry mouth, 
constipation, insomnia. 
 
Rimonabant Accomplia 
Treatment group 
lost 4.7kg more 
weight than 
placebo group. 
Mood swings and gastrointestinal side effects. 
Contraindicated for subjects on anti-depressants. 
6% of the subjects in the treatment group 
experienced serious adverse events (depression, 
anxiety, irritability and aggression) compared to 
4% of the subjects in placebo group. 
Approved for short-term treatment (up to 12 weeks) 
Phentermine Bontril Only short-term 
studies are 
available and 
weight loss was 
significantly more 
in treatment 
group. 
Long-term use may promote tolerance, 
prompting an increase in the dosage of drug. 
Diethylpropion Tenuate, 
Tepanil 
Same as above. 
Mazindol Mazanor Appetite reducing effects decrease after a few 
weeks of using Mazindol, hence not effective 
for long-term use. 
Approved for other purposes, but have the effect of promoting weight-loss 
Metformin Glucophage 
Not indicated 
for weight loss. 
Used for diabetic treatment 
Bupropion Wellbutrin Used as an antidepressant 
Zonisamide Zonegran Antiepileptic 
Topiramate Tomapamax Antiepileptic 
 
Although the FDA approves the drugs listed in Table 4 for their efficacy and tolerable side 
effects, they are not the first line of treatment for overweight and obese individuals. There are 
recommended treatment plans by the National Institute of Health
 64
 that suggest one should 
start treatment with diet modification and exercise and only move onto pharmacotherapy once 
these interventions show minimal or no effect on weight loss.  In addition, while these drugs 
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may have an effect on weight loss during the treatment period, weight regain is common at 
the cessation of therapy; subjects still require alternate therapy to avoid weight cycling. 
If one considers obesity as a clinical disease, there are currently no cures for it. Weight loss 
drugs can be a temporary effective solution for some or can be used as an adjunct to other 
core therapies that involve lifestyle intervention. 
1.2.4.2 Over-the-counter (OTC) medication / dietary supplements 
There are a great number of OTC weight-loss products currently available on the market and 
this is mostly due to the ease with which products are allowed to appear in the market without 
adhering to stringent regulations, as well as popular demand from the consumers. See below 
for a list of reasons for using dietary supplements. Such products are appealing to the general 
public, as they are often reinforced by attractive marketing schemes. Intensive advertising 
often suggests the product’s effectiveness via simple testimonials, which have no scientific 
basis. While the prevalence of obesity is increasing at an alarming rate, the general public 
does not consider it as a disease. Instead, people associate it with laziness and lack of 
willpower
 65. As a result, there is a lack of urgency to seek medical professionals’ help, 
leading many consumers to purchase one of the easily accessible products that make up the 
multi-million rand market. Box 1 lists the reasons that consumers turn to using dietary 
supplements. 
Box 1:Reasons for using dietary supplements
 65
 
Reasons for using dietary supplements  
- Belief that they are effective 
- There is a stigma associated with overweight and obesity 
- Benefit of a healthier body 
- Consumers desire a quick and easy fix 
- Requires less effort from the consumers compared to exercise and 
lifestyle changes 
- Failure of previous attempts at exercise and/or dieting 
- Easily accessible as they do not require a prescription 
- Attractive advertising claims 
- Perception that the product is safe as most products claim to be natural 
substances 
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South Africans are currently spending over R900 million a year on dietary supplements, 
including vitamin and mineral supplements, weight-loss drugs and body-building 
supplements
 66
. The demand for natural herbal supplements is expanding due to the public’s 
increased awareness of health products, fitness centres which advocate them, recent 
publications on the importance of nutrition in health and effective marketing programmes. 
As popular as these products are, most lack clinical data to support their effectiveness. 
Therefore, a moderate side effect can easily shift the risk-benefit ratio and discourage the use 
of such products. 
1.2.4.3 Bioslim 
In this study, we have chosen to investigate Bioslim as an example of one of the many 
products available on the market which is also vigorously promoted (it claimed at one time to 
have a 51% market share of this class of products)
 67
. It is one of the dominant weight-loss 
products on the market and is easily accessible to consumers without prescription. Several 
randomised controlled trials have taken place to study some of the individual active 
ingredients contained in Bioslim, with no robust evidence having shown any to be efficacious 
in weight loss at the doses tested in those studies
 68, 69
. However, as is the case with many 
other weight-loss products, no clinical trial has been done that tests the entire product’s 
effectiveness as a weight-loss drug. 
Table 5 lists the ingredients comprising Bioslim Once a Day. Pyruvate and Citrus aurantium 
are the two key ingredients found in Bioslim Once a Day, and the daily dosage is roughly 
230mg and 200mg respectively. 
Table 5: Ingredient list in each of the 3 capsules found in Bioslim Once a Day 
Loss Accelerator – each capsule contains 
(One tablet per day for the next 7 days) 
Calcium pyruvate 200mg 
Citrus aurantium 150mg 
Gotu kola 100mg 
Guarana 50mg 
Ginger root 48mg 
Cascara sagrada 30mg 
White Willow Bark 20mg 
Garciniacambogia 15mg 
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Slimtone – each capsule contains 
(One tablet per day for the next 28 days) 
L’CarnitineFumarate 80mg 
Citrus aurantium 50mg 
Calcium pyruvate 30mg 
Botanical Herb Blend 25mg 
Calcium Ascorbate 1.25mg 
Pyrodoxine as HCl 333mcg 
Chromium as Picolinate 16mcg 
 
Nutri-Vitamin – each capsule contains 
(One tablet per day for the next 28 days) 
% RDA/AI 
70
 
contribution for 
adult female 
% RDA/AI
 70
 
contribution for 
adult male 
Ascorbic Acid 55mg 73% 61% 
Botanical Herb blend 55mg - - 
Prune concentrate 50mg - - 
Magnesium 40.4mg 12.6% 10.1% 
Choline Bitartrate 24mg - - 
Nicotinic Acid (vit. B3) 12.6mg 90% 78.75% 
Kelp Powder (deiodised) 12.4mg - - 
Citrus Bioflavanoid 8.4mg - - 
Inositol 8.4mg - - 
Vitamin E ( - TE) 7.2mg 48% 48% 
Calcium Pantothenate (vit. B5) 5.5mg 110% 110% 
Calcium 4.6mg 0.46% 0.46% 
Zinc 4mg 50% 36.36% 
Pyrodoxin HCl (vit. B6) 2.51mg 167% 193% 
Vitamin B1 2mg 182% 166% 
Vitamin B2 1.8mg 163% 138% 
Manganese Glycerophosphate 1.7mg 34% 34% 
Ferrous 130mcg 0.72% 1.63% 
Vitamin A (RE) 69mcg 0.01% 0.01% 
Folic Acid 67mcg 0.02% 0.02% 
Chromium as Picolinate 67mcg 0.27% 0.19% 
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D-Biotin 50mcg 0.17% 0.17% 
Potassium 17mg 0.36% 0.36% 
Copper 8mcg 0.88% 0.88% 
Vitamin B12 3mcg 0.13% 0.13% 
Cholecalciferol (vit. D3) 0.03mcg 0.00% 0.00% 
 
Analysis of the Bioslim ingredient list shows that although some of the micronutrients, such 
as Vitamins B1, B2, B5 and B6, exceed the Recommended Daily Allowance
2
 (RDA), none of 
them exceed the Upper Limit (UL) where the UL figure is available. 
Ingredients such as pyruvate and L’Carnitine, which claim to increase fat oxidation and 
reduce fat synthesis 
71, 72
, have shown minimal or no effect in studies, or their effectiveness 
has not been conclusively confirmed. Where there is some evidence of possible efficacy, the 
dosage used in this product is questionable. For example, studies of pyruvate have shown 
minimal effect on weight loss when subjects consume 6g per day divided over 3-4 doses per 
day. However, Bioslim claims its effectiveness using only 2.3g of pyruvate once per day
 72
. In 
one study, Guarana extract (Paulliniacupana), used in conjunction with ephedra, has shown 
short-term effectiveness in weight loss, but no study of Guarana on its own has shown any 
effectiveness
 73
.  
The ingredient, Citrus aurantium, otherwise known as bitter orange, which is similar to 
ephedra, contains an adrenergic agonist such as synephrine alkaloids. Ingesting 50mg of 
synephrine has the potential to raise systolic blood pressure, diastolic blood pressure and the 
heart rate of a young healthy adult for up to 5 hours
 68,  74,  75
.  Since the banning of ephedra in 
April 2004, sales of dietary supplements for weight-loss purposes have dramatically increased
 
76
. Some of the banned ephedra-containing products simply substituted the ephedra with 
Citrus aurantium. According to the Federal Trade Commission, Citrus aurantium is one of 
the five most popular ingredients that are found in over-the-counter (OTC) weight-loss 
products, as it claims to promote energy expenditure and suppress appetites
 61
. Trials (see 
Table 6) conducted to investigate the efficacy of this ingredient have shown some positive 
results in the promotion of weight loss when compared to placebo groups
 69, 77, 78
. However, 
these studies have had small sample sizes, used large doses, and no long-term study has taken 
place. In addition, it is hard to differentiate the effect of Citrus aurantium from other 
ingredients when these studies also included other herbal substances such as caffeine, St. 
John’s Wort and Guarana. One published randomized, double-blind, placebo controlled trial 
                                                     
2
 Or Adequate Intake (AI) when RDA is not available 
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using Citrus aurantium in weight-loss, at a dose far greater than present in Bioslim, found 
that subjects (n = 9) in the active ingredient group showed a significant weight loss of 1.4kg 
after 6 weeks, whereas the placebo group (n = 7) showed little or no changes
 69
. All of the 
subjects received individualized instructions from a dietician to follow a 1800kcal/day 
American Heart Association Step One diet and to engage in a 3 day per week circuit training 
exercise programme with a physiologist. Other trials investigating the effect of Citrus 
aurantium have an even smaller sample size, and showed conflicting results 
69, 77, 78, 79
. 
Table 6: Summary of four weight-loss trials that used Citrus aurantium as part of their 
anti-obesity treatment
 61 
Study 
Main ingredient 
(daily dose) 
Study design Duration Result 
Colker et al.
 69
 
975mg Citrus aurantium 
528mg caffeine 
900mg St John’s Wort 
versus 
Placebo (with pill) and 
control (with no pill). 
Blinded parallel 
groups. 
Randomized 
controlled trial. 
Active, N  9 
Placebo, N  7 
Control, N  4 
No dietary 
restriction. 
6 weeks Active group lost a 
significant amount 
of body weight (-
1.4kg, p < 0.05) 
and placebo group 
did not (-1.1kg, p 
< 0.1). 
No adverse events 
were reported. 
Jones et al. 
77 
325mg Citrus aurantium 
(equates to 5mg of 
synephrine alkaloid) 
125mg Paullinia cupana 
5mg Ginkgo biloba 
Open labelled. 
Week 1: 3800-4200 
kJ/day diet, 
followed by week 
2: using the 
supplement. 
N  9 
2 weeks Week 1: an 
average weight 
loss of 0.94kg was 
found. 
Week 2:  an 
average weight 
loss of 2.4kg (P < 
0.05).  
Kolman et al.
 
78
 
Ephedrine and synephrine 
alkaloids (derived from 
Citrus aurantium), 5mg 
twice daily. 
versus 
placebo 
 
Double blinded, 
randomized 
controlled, 
prospective trial. 
N  30 
All groups 
exercised and 
advised 
8weeks Significant weight 
loss found in the 
active group (- 
3.4kg) than the 
placebo group (-
2.05). p  0.05 
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22kcal/kg/day diet. 
Armstrong et 
al.
 79
 
85mg Citrus aurantium 
(5mg synephrine) 
335mg Ma huang (20mg 
ephedrine) 
40mg Pantothenic acid 
910mg Guarana extract 
(200mg caffeine) 
105mg Willow bark 
extract (15mg salicin) 
50mg ginger root 
versus 
placebo 
Randomized trial 
Active, N  12 
Placebo, N  8 
No dietary 
restriction. 
44 days Active group (-
2.5kg) showed a 
significantly 
higher fat mass 
loss than placebo 
(-0.5kg). p  0.033 
 
These results suggest that Citrus aurantium in specific doses may have some benefit in 
enhancing weight loss when incorporating exercise and diet. However, none of these trials 
were rigorous or exceeded 6 weeks or used more than 20 subjects, consequently limiting the 
strength of these findings.  
Although some of the Citrus aurantium trials reported significant weight loss compared to the 
baseline or the placebo group, the actual weight loss was less than both the stipulated criteria 
required by the FDA and the CPMP. This means that none of the products used in these trials 
can be considered to have a clinical benefit. 
While the effectiveness of Citrus aurantium still needs to be confirmed, the adverse effects 
require some attention as several incidents of stroke, myocardial infarction and tachycardia 
have been reported
 75
. Health Canada also reported 16 cases relating to the usage of Citrus 
aurantium where individuals experienced severe adverse effects such as tachycardia, 
ventricular fibrillation and cardiac arrest. The WHO subsequently issued an alert to health 
authorities regarding the use of this ingredient
 80
. In South Africa, a young healthy 
bodybuilder who had no previous cardiovascular disease, consumed herbal supplements, 
including Citrus aurantium, to improve his performance and was reported to suffer from an 
acute myocardial infarction attack
 81
. There may have been more adverse events, but the 
current surveillance system is poor and reports of such incidents are not compulsory. 
Most unsubstantiated weight-loss products use polypharmacy (i.e. a combination of 
ingredients). Yet, actual clinical testing of the efficacy and safety of these combinations of 
ingredients has not taken place.  Methylxanthines, such as caffeine, are found in various 
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plants such as Guarana and green tea
 74, 82
, which are both part of Bioslim’s active ingredients. 
Caffeine stimulates the central nervous system and increases systolic blood pressure which 
may pose a danger to consumers with cardiac diseases. Individual ingredients on their own 
may not show any adverse effects, but the combined effect of them is not known. There is no 
evidence of whether or not these combinations have a synergistic or an antagonistic effect, 
which may result in enhanced toxicity. 
The other Bioslim ingredients are not discussed here as they play a minor role, for they are 
used in miniscule amounts in comparison with the individual ingredients already mentioned. 
Another well-known weight-loss product, Herbalife, also uses common herbal ingredients and 
is therefore often considered “natural” and safe by consumers. Herbalife has recently been 
associated with severe hepatotoxicity
 83, 84
. In a recent study, cases of acute liver injury were 
reported in association with Herbalife usage
 83
. In some cases, the damage was reversed when 
intake of Herbalife ceased. Another example of a potentially dangerous ingredient when taken 
in the wrong combination is St. John’s Wort (Hypericumperforatum), which is toxic when 
ingested with medications such as antiretroviral drugs and may also cause photosensitivity
 85
. 
Potential adverse effects for the most relevant ingredients are listed in Table 7. 
Table 7: Adverse effects relating to specific ingredients 
Ingredient name Product Efficacy Possible adverse events 
Citrus aurantium 
Inadequate clinical evidence to 
support efficacy
 86
.  
At a high dosage (adverse events 
have been found after a single dose 
of 900mg of Citrus aurantium, 
which is an equivalent of 54mg of 
synephrine. In this study, 
participants are taking 200mg of 
Citrus aurantium per day.) Because 
of its stimulant effect, it may cause 
hypertension and cardiovascular 
toxicity such as: ischemic stroke, 
cardiac arrest, angina, myocardial 
infarction.  
Gotu kola 
Most studies use this in 
combination with other herbal 
ingredients. None show effective 
long term weight loss
 87
.  
May cause nausea, gastrointestinal 
upset. There have been 3 reported 
cases of hepatoxicity associated 
with the intake of Gotu kola, 
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dosage unknown. 
Guarana Little evidence for efficacy
 86
.  
Adverse effects are related to the 
amount of caffeine content 
(Guarana contains caffeine). High 
dosages can cause gastric irritation, 
nausea, vomiting, restlessness, 
insomnia, tachycardia, tremors and 
chest pains.  
Cascara sagrada Little evidence for efficacy
 71 
Mild gastrointestinal irritation. 
Long term intake may induce 
hypokalaemia, muscle weakness, 
cachexia and disturbed heart 
function (In this study, participants 
will be taking Bioslim for the 
period of one month only.)  
L’carnitine Little evidence for efficacy 71 
May cause gastrointestinal 
disturbances such as abdominal 
cramps, diarrhoea, nausea and 
vomiting. As well as heartburn, 
gastritis, body odour and seizures. 
Pyruvate Little evidence for efficacy
 71 
May cause gastric distress.  
Willow bark (salicylates) 
Most studies use this in 
combination with other herbal 
ingredients. None show effective 
long-term weight loss
 71
.  
May cause gastrointestinal 
irritation. In people who are allergic 
to aspirin, it can cause allergic 
reaction such as itching, as well as 
severe reactions such as 
anaphylaxis. 
 
1.2.5 Adverse effects associated with usage of weight-loss drugs 
Adverse events due to the ingestion of weight-loss drugs are difficult to monitor because of 
the lack of surveillance, authoritative regulation and registration of dietary supplements, as 
well as the vast number of products available in the market. Specific ingredients’ adverse 
effects are also difficult to investigate in clinical trials, as most studies use a combination of 
herbal substances, and consequently it is difficult to relate specific side effects to one 
ingredient. In particular, if the adverse effects are rare, they are often undetected without a 
stringent surveillance structure. 
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Palmer and colleagues carried out an observational study that included 21 poison control 
centres in the USA
 88.
 They found that 33% of the adverse events reported to the centre were 
related to dietary supplements. Of these events, 70% were regarded as mild (with minimal 
consequences and short term effects), 24% as moderate (systematic, e.g. an isolated seizure or 
arrhythmia with hypertension), 6% severe (life-threatening e.g. respiration compromised and 
requiring intubation) and 1% resulted in death
 89
. Similar findings were reported in other 
studies
 90, 91
. It was further found that most of these events were associated with herbal 
substances such as Ma huang (Ephedra sinica) (thought to be responsible for the toxicity of 
Herbalife), Guarana, ginseng (Panaxgenus) and St John’s Wort. 
Moreover, negative events were found to be significantly more frequent in individuals 
ingesting multiple ingredients, rather than single ingredients. Most OTC weight-loss products 
on the market use polypharmacy (with no proof of synergistic, antagonistic or other types of 
interactions). In fact, they often advertise this fact to promote the efficacy of the product, 
claiming that the potency of the drug is now strengthened and yet the side effects have been 
reduced as a result of the use of polypharmacy. Dietary supplements similarly lack the 
endorsement of clinical studies to ensure the safety of long-term ingestion. Persistent 
supplement usage may lead to the build-up of chemicals and increase the toxicity in tissues
 92
. 
A review by Lenz and Hamilton
 72 
reported that 80% of overweight or obese individuals do 
not seek medical professional help for their first attempt at weight-loss. This is of concern, as 
hypertension is often found in overweight and obese individuals and some dietary 
supplements such as caffeine, Citrus aurantium and Guarana have been shown to raise blood 
pressure and hence contra-indicate the usage of such substances
 93
. Most individuals assume 
that these herbal substances are natural and harmless, and are therefore unlikely to report the 
usage of a dietary supplement to their doctors (which may compound potential side effects of 
drugs already being taken for other pre-existing conditions). In fact, their use may be a hidden 
practice
 94
. Lack of help from medical professionals may hinder individuals from receiving 
scientifically sound information on healthy weight-loss methods, further exacerbating the 
problem of obesity. Findings from NHANES III suggested that individuals might start using 
OTC weight-loss drugs in place of lifestyle changes
 95
. 
Other adverse events frequently associated with dietary supplement use are myocardial 
infarction, coagulation disorders, anaphylaxis and hepatic disease
 89
. A further concern is that 
consumers report frequent usage of herbal substances to treat diseases and use them as 
prescribed drugs, which is not the intended indication. There seems to be confusion over the 
difference between prescription products and dietary supplements, which reinforces the need 
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for government regulation, particularly as the manufacturers may promote the dietary 
supplement as a highly effective equivalent to prescription medication, but even better, 
because it is safe and made from natural ingredients. 
1.3. Regulation of weight-loss drugs and dietary supplements 
All prescription weight-loss drugs, such as Orlistat, are currently regulated by the Medicines 
Control Council (MCC) under the Medicines and Related Substances Control Act (MRA) 
(Act 101 of 1965)
 96
.This act regulates the manufacturing, distribution, sale, and marketing of 
medicines to ensure that they are safe and effective for consumers as indicated by 
scientifically sound clinical trials. 
However, all nutritional supplements, specifically ones marketed to aid weight-loss, may not 
be considered as medicine, but as complementary medicine. This means that there is no 
requirement for clinical trials before they appear in the market.  Hence the efficacy, safety, 
product quality and accuracy of claims are not tested nor controlled. Furthermore, the actual 
regulation around complementary medicine is still a perplexing issue. According to the 
Principal Medicines Regulatory Officer of MCC
 97
, a government gazette has been issued in 
2002, acting as a call-up notice for all the products that are available in the market and refer 
to themselves as complementary medicines in terms of the Medicines and Related Substance 
Control Act, 1965. 
According to the Act, medicine is defined as 
any substance or mixtures of substances used or purporting to be suitable for use of 
manufacture or sold for the use in: 
a) diagnosis, treatment, mitigation, modification, or prevention of a disease, or 
abnormal physical or mental state, or the symptoms thereof in man, or 
b) restoring, correcting, or modifying any somatic or psychic or organic function in 
man, and includes any veterinary medicine. 
All medicines for human use are subject to this law, including complementary and 
complementary biological medicines. 
This call-up process would assist with the auditing of all products not only for registration 
purposes, but so that MCC could review their claims of safety, quality and efficacy, with the 
aim of determining if these product pose a public hazard or not. However, this auditing 
process was never promulgated. 
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To further complicate the issue, a call-up process seems unnecessary if according to section 
14 of the Medicine and Related Substances control Act there is: 
14. Prohibition on the sale of medicines, which are subject to registration and are not 
registered. 
In October 2009, the MCC was about to rescind the 2002 “call-up” in order to prevent further 
misunderstanding and abuse of this flawed process, but was threatened with legal action by 
the “complementary” medicine industry and it was therefore not followed through 67. 
In comparison, the USA’s medicine regulatory body, the FDA (Food and Drug 
Administration) defines a dietary supplement as a product that is taken by mouth and contains 
‘dietary ingredients’ intended to supplement the diet. The ‘dietary ingredients’ in these 
products include vitamins, minerals, herbs or other botanicals, amino acids, and substances 
such as enzymes, organ tissues, glandulars, and metabolites
 59
. 
These dietary ingredients are regulated under the Dietary Supplement Health and Education 
Act (DSHEA) of 1994, which is meant to provide consumers with easy access to dietary 
supplements without a prescription and to allow manufacturers to push products onto the 
market without following the regulations of the Federal Food, Drug and Cosmetic Act (for 
drugs) and consequently no requirements for carrying out clinical trials to test their efficacy 
and safety. According to the act, all dietary ingredients that were marketed before 1994 are 
considered to be safe, and all new ingredients that are introduced after this date will require 
the submission of a pre-marketing notification to the FDA to review the information that is 
submitted by the manufacturers, such as published journal articles. Otherwise, it is the 
manufacturer’s responsibility to ensure that the product is safe and that the labelling is 
truthful. In addition the act relies heavily on the public and the manufacturer themselves to 
voluntarily report any adverse events or defective products
 98
. Although the USA may have 
clearer defined regulations for complementary medicine, the availability of products with 
unlawful and unsubstantiated claims for weight-loss are still commonly found there. As 
Americans are some of the highest spending consumers of diet programmes and related 
products, at an estimated amount of 30 billion dollars a year, it is hard to keep up with all the 
products and manufactures still finding ways to enter the market under the registration of 
dietary supplements and not as medicines. According to the Federal Food, Drug, and 
Cosmetic (FD&C) Act, under the labelling section, if the labelling includes: 
a claim relating to an effect on the structure or function of the body, a claim of 
general well-being, or a claim of a benefit related to a classical nutrient deficiency 
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disease, the product must bear a disclaimer stating that FDA has not evaluated the 
claim and that the product is not intended to diagnose, treat, cure or prevent any 
disease. 
This act is an attempt to discourage manufacturers from registering products under dietary 
supplements in order to avoid stringent clinical trials, but still claiming the effect of a 
registered medicine. However the USA Federal Trade Commission (FTC), which is 
responsible for the monitoring of the advertising and marketing of products, does not always 
reinforce the Act stringently and some dietary supplements that violate the Act can still be 
found in the market.  An example of the FTC charging a diet pill company for deceptive 
advertising and corrupt practices is that of Sistema Silueta. The advertiser of this cellulite 
reduction product made false claims that this product could break down cellulite and fat when 
the cream was applied to the body. It further stated that the treatment would penetrate the skin 
and dissolve the fat cells to reduce cellulite in the buttocks, and that the body would then 
excrete them. The FTC has been able to successfully refute such claims, and in order to 
protect the consumers, has prohibited the company from manufacturing any cosmetic or drug 
in the future that would transgress the act. 
In South Africa, the MCC sets the rules and the regulations like the FDA, but the MRA 
enforces such legislation. The MCC has been revising regulations relating to medicines, and it 
is believed that it contains a section governing so-called “Complementary medicines”. 
However, while the MCC is finalising the complementary medicine regulations and 
registration procedures, manufacturers of dietary supplements are not without any restraints. 
Other regulatory bodies such as ASA (Advertising Standards Authority of South Africa) have 
also laid out a Code of Advertising Practice for the complementary medicine industry to 
adhere to
 99
. ASA is an independent body set up by the marketing communication industry to 
self-regulate advertisements in the general consumers’ interest. 
This code is based on the International Code of Advertising Practice, prepared by the 
International Chamber of Commerce. According to the ASA code these are some of the 
unacceptable claims: 
 “Product X is safe” 
“Contains no harmful substitutes with side effects” 
And/Or 
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Claims implying that this product is a medicine i.e. interfering with the normal physiology of 
the body, e.g. 
“Product X increases/speeds up metabolism” 
“Product X melts fat away” 
“Product C makes fat cells shrink” 
“Product X contains bio-active ingredients” 
And/Or 
Claims that quantify mass loss: 
If the expected mass loss is quantified for a product, the amount stated shall not exceed 1kg 
per week, as this is the accepted level for safe mass loss. Furthermore claims such as “Helps 
you slim fast” and “Easy weight loss” etc. are not permissible. 
Despite the clearly stated advertising guidelines, such claims can still be found often on TV, 
product packaging and in magazines. 
The Federal Trade Commission found that weight-loss advertising is mostly full of 
misleading claims, since 40% of the adverts make at least one claim that is almost certainly 
false, and 55% make at least one that is likely to be false. Nearly 50% of the adverts that were 
included in the survey promised weight loss without dieting or exercise
 100
. 
Other popular marketing gimmicks that are often found in adverts are testimonials. Although 
these are not prohibited by the ASA code, it requires that the testimonials be genuine and 
substantiated. All photographs should be dated and signed by the person in the included photo
 
99. However, it is questionable whether the individual’s weight loss in the testimonial is due to 
the actual product being marketed or other interventions such as a very low caloric diet and 
intensive exercise. 
The ASA code provides a good basis for ethical advertising, but there is no formal 
surveillance body for illegitimate adverts and ASA relies on the general public, specifically 
health professionals, to report any violation of their codes to ensure that all of the 
manufacturers’ marketing is compliant. 
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1.4. Negative impact of perpetual dieting attempts 
The vast number of weight-loss products is overwhelming for the consumers; nevertheless the 
market is constantly expanding with new products, each with a persuasive infomercial 
guaranteeing weight loss. Most of these weight-loss drugs have no effect at all; some result in 
temporary weight-loss in some individuals. Whatever the case, as in an energy-restricted diet, 
the weight that was lost is generally regained when the diet or drug therapy ceases, or there is 
regression to the mean, leading to weight cycling. 
“Weight cycling” can be defined as fluctuation in weight, specifically led by a series of 
unsuccessful dieting attempts in which the subject regains the weight that was previously lost. 
Some studies speculate that obese and overweight people might have a down-regulation of 
resting metabolism post weight-loss, causing them to be obesity prone, and that chronic 
dieters may have a lower-than-normal resting energy expenditure
 101
. These speculations are 
not supported by most studies; what is certain, however, is that frequent fluctuation of weight 
has a negative impact on health. 
A Women’s Ischemia Syndrome Evaluation (WISE) study found that there was an association 
between high-density lipoprotein cholesterol (HDL-C) and weight cyclers. HDL-C was on 
average 7% lower in weight cyclers than non-cyclers. This effect is dose dependent, as 
women who had lost 22.7kg in each cycle had 21% less HDL-C compared to their 
counterparts
 102
. The Framingham study further validates this by showing a positive 
association between weight variations and an increased risk of coronary heart disease
 103
. 
From the psychological point of view, perpetual unsuccessful attempts at weight loss may 
have a negative impact on one’s self-esteem, resulting from the negative connotations 
associated with being overweight or obese
 104
. Various studies have shown that the media 
often stereotype overweight individuals as unattractive, unsuccessful and socially inept
 60
. 
Furthermore most dieting pills guarantee weight loss or decrease in fat mass, backed by 
claims such as a “30-day payback guarantee”, and some implicitly suggest that a result can be 
achieved with unrestricted eating and in the absence of exercise. As a result, consumers are 
led to believe that the pill is the key to success, so that if weight loss is not achieved then the 
fault must lie with them. Meanwhile, the pill itself may not have had any effect to begin with. 
Thus, one can see how weight-loss drugs may not only have dangerous clinical side effects, 
but can also negatively influence consumers psychologically by exacerbating low self-esteem 
and related psychological issues. They can also delay individuals from seeking professional 
help which may impact on their health, e.g. type 2 diabetes or hypertension can become 
uncontrolled or irreversible unless there is an intervention early on. 
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1.5. Placebo effect 
As in most clinical trials, a placebo group is included in this randomised control study to 
ensure that any effect observed in the active-pill group is not due to the placebo effect, which 
is defined as the therapeutic effect of an inert drug and used to validate drug effectiveness
 105, 
106
. As the effect of a drug that is measured from an interventional trial, is the result of various 
elements and not only the outcome of the pharmacological effect, factors such as regression 
to the mean (including the number of subjects, trial duration, design of the study and the end 
measure of responses), natural remission of the disease and placebo response (due to the 
administration of the drug) also have an impact on the effect measured
 107
. The placebo group 
is therefore used to control these other factors. For a drug to be proven to be effective, the 
outcome measure should be significantly greater in the treatment group than in the placebo 
group.  
It is difficult to predict and measure the actual placebo effect, as different outcome measures, 
disease profile and the history of the disease can influence the response rate. Nonetheless, it is 
commonly thought that 30% of the subjects in the placebo control group experience placebo 
effects. According to Beecher’s result 108, a wide range of response rates, varying from 7% to 
49% have been observed in various studies
 109
. Hrobjartsson and Gotzshe carried out a meta-
analysis study in 114 trials relating to the placebo effect and found that a significant 
difference between the placebo group (that receives treatment with no effect) and a non-
treatment group (group that receives no treatment at all) is only observed when the outcome 
measure is something self-reported and subjective, e.g. pain. Hence, an outcome measure that 
requires objective reports, e.g. observation of blood pressure or asthma, may have a much 
lower placebo response rate compared to subjects’ reports of pain 109. 
One of the possible mechanisms for placebo effect may be explained by classical 
conditioning. The act of taking a drug can be regarded as a conditioned stimulus, due to its 
visual, tactile and gustatory effect on the individual. Repeated measures of this act can be 
paired with the unconditioned response. For example, whenever one takes a painkiller it 
resolves the pain of a headache. When the pill is switched to an inert drug, the conditioned 
stimulus, the act of taking the drug, can still elicit an unconditioned response, resolving of the 
pain
 110
, as the stimuli triggered by the placebo can activate the release of various 
neurotransmitters and modulators that bind to the same receptor to which the actual chemical 
of the drug would bind - thus prompting the same pharmacological effect
 107
. But can the 
same effect be experienced when taking a weight-loss drug? 
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The placebo effect is believed to be modulated heavily by the role of expectancy, which is 
defined as the individual’s expectation regarding the progress of the disease and is directly 
related to the individual’s belief in the efficacy of the administered drug 111. As illustrated in 
the sports field, the mind has a great impact on performance; study results have shown that, 
performance can be greatly improved by prescribing placebo pills without actual ergogenic 
effect, depending on the athlete’s belief in the efficacy of the substance 112. 
 
Similarly, the power of advertising can also play on the individual’s mind and encourages 
individuals to expect highly effective drugs for weight loss. The placebo effect is then 
enhanced when subjects believe in the effectiveness of the pill, as suggested by convincingly 
authoritative sources such as the media or testimonials. Studies have shown that, even though 
the placebo effect is due to psychological belief, it can evoke physiological reactions. This is 
illustrated by studies from Columbia and Michigan universities
 113
, in which volunteers took 
an inert substance and believed that they had been given a potent painkiller. It was observed 
that some of these volunteers released opioids (the body’s natural physiological pain-relief 
mechanism) and the pain was subsequently relieved. See Table 8 for a list of other 
physiological reactions that can be triggered by the placebo effect. Thus, when consumers 
trust the effectiveness of an ineffective weight-loss drug, it may result in them losing weight 
as a result of subconscious psychological responses (for example, potential hormone changes 
that promote metabolism, or the subject making conscious or unconscious modifications to 
diet or exercise). 
 
Table 8: Possible physiological responses that are elicited when a placebo is 
administered
 107
 
 
Disease / system for the targeted drug 
effect 
Possible mechanism or physiological 
response to placebo treatment 
Pain 
Release of endogenous opioids and 
cholecystokinin. 
Parkinson’s disease  
Dopamine released in the striatum changes 
the firing pattern of sub thalamic nucleus 
neurons.  
Depression  
Brain metabolism changes and possibly 
inhibits serotonin reuptake. 
Cardiovascular system 
Reduction of -adrenergic activity of the 
heart. 
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Immune system 
Immune mediators such as lymphocytes can 
be preconditioned by actual 
immunosuppressive drugs. 
Endocrine System  
Hormones such as the growth hormone are 
preconditioned.  
 
 
As part of the marketing scheme, attractive packaging can also influence subjects’ 
expectancy, which was illustrated by Kienle and Kiene et al.
 114
. Packaging, colour and size of 
the pill have an impact on the individual’s perception of the drug. For example, red is 
believed to be more stimulating and pale colours, in contrast, to be more relaxing. In addition, 
conditioning can also have an effect, as individuals can associate various therapeutic 
procedures and ways in which drugs were administered (intravenously or by ingestion) from 
their past and then pair the experience with successful treatment of a disease. Thus, an 
individual may pair an intravenous injection to a more successful treatment result or the 
effectiveness of the drug may be more convincing when three pills (as found in the Bioslim 
Once a Day package) are prescribed than one
 115
.  In this study the placebo group is not only 
included for the validation of the drug’s effectiveness, but also to investigate whether 
aggressive marketing schemes such as persuasive TV adverts, appealing packaging and 
testimonials further add to the power of the placebo effect and how this group compares to 
groups receiving placebo pills in “no name” packaging. 
 
Wansink
 116
 has reported that an individual may unconsciously make or consider over two 
hundred food-based decisions a day, and therefore any factor that makes any of these 
thoughts conscious, may result in the individual altering that “food script” and may result in a 
change in that individual’s behaviour towards food, e.g., to eat less. Therefore an individual 
taking an inert substance may still lose weight as a result of becoming conscious of food 
intake
 116
. 
 
1.6. Anthropometry 
1.6.1 Weight measurement and BMI 
One of the most commonly used nutritional assessments is weight measurement. It is either 
recorded as part of weight history to observe any fluctuation or combined with the 
individual’s height measurement, in order to work out the body mass index (BMI). This is 
also known as Quetelet’s Index and is calculated by taking the weight (kg) of the individual 
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divided by the square of his/her height (m)  and is used because weight on its own provides 
little anthropometric information about the individual. This measurement is recommended by 
the National Research Council’s Committee on Diet and Health 117 as a tool to assess 
overweight or underweight individuals. It is also commonly used in National surveys, such as 
the NHANES
 26
 from the USA and National Food Consumption Survey
 7
 in South Africa. 
BMI is easy and practical to use in the clinical setting and its classification has been 
developed by the Expert Panel on the Identification, Evaluation and Treatment of Overweight 
and Obesity in Adults and endorsed by WHO
 4
. Table 9 shows the BMI classification cut-off 
points for the various degrees of overweight, which are identified by the association found 
between mortality risk and BMI
2
. It has also been shown to predict total adipose tissue with 
an error of 10% or less when compared to CT results. Although it may be a good indicator for 
excess fat mass, it does not take age, gender or individuals with extreme body composition 
into account. For example, BMI maybe overestimated in very muscular individuals such as 
body builders or underestimated in the elderly with loss of lean mass
 117
. 
To improve the usefulness of BMI in body fat mass prediction, the WHO has recommended 
the inclusion of waist circumference when carrying out nutritional assessments. Hence BMI 
and waist circumference can classify individuals for overweight and abdominal fatness 
respectively
1
. Furthermore, as indicated in Table 9 waist circumference and BMI are able to 
estimate mortality risk. 
Table 9: Classification of obesity and associated health risk with waist circumference
 64 
 BMI (kg/m
2
) Obesity 
Class 
Disease Risk according to BMI and 
waist circumference 
 Men  102cm 
Women  88cm 
Men > 102cm 
Women > 88 cm 
Underweight < 18.5  - - 
Normal 18.5 – 24.9  - - 
Overweight 25.0 – 29.9  Increased High 
Obesity 
30.0 – 34.9 
35.0 – 39.9 
I 
II 
High 
Very High 
Very high 
Very high 
Extreme 
Obesity 
 40 III Extremely high Extremely high 
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1.6.2 Skin-fold measurement 
Obesity is defined as an accumulation of excess fat. In order to monitor the progress of 
treatment for overweight and obesity, the skin-fold assessment tool is used in measuring body 
composition, specifically changes in total fat mass. Various other methods and pieces of 
equipment have been developed to analyse body composition, such as under water weighing 
(UWW) and dual-energy X-ray absorptiometry (DXA), which are regarded as valid and 
reliable reference methods. However, such equipment is often not available due to cost and 
lack of trained operators
 118
. 
For a more portable and accessible method, anthropometric techniques may be considered. 
One of these techniques is the measurement of skin-fold-thickness with a calliper at various 
sites on the body. The calliper is used to measure the subcutaneous fat. The operator then 
estimates the total body fat by converting these measurements, using various prediction 
equations for specific population groups
 119
. Besides being an easily accessible tool, skin-fold 
measurement is also a non-invasive, painless and cost-effective method of estimating body fat 
mass. Researchers can easily be trained to correctly operate the calliper, and in addition to test 
the inter- and intra-rater reliability to ensure accuracy. The skin-fold measurement method 
was adopted in the NHANES as one of the tools to assess overweight and obesity
 120
. 
Accuracy of skin-fold measurement depends heavily on the appropriate choice of a prediction 
equation, as different subject groups have varying fat-free mass density, dependent on age 
and sex. For example, women have a lower fat-free mass density than men. Therefore, fat 
mass is often overestimated when the value for fat-free mass density is assumed to be the 
same as for men. Durnin and Womersky attempted to overcome this problem by developing a 
series of prediction equations that are age- and sex-specific and can also be used in general 
population groups
 121
. Durnin and Womersky’s prediction equations were further supported 
by Andrade et al.
 122
, who tested them against a reference method, namely magnetic resonance 
imagining (MRI). The results from the MRI and the skin-fold measurement were found to be 
in good agreement. A study by McNeil et al.
 123 
indicated that skin-fold measurement has an 
accuracy comparable to other techniques such as bioelectric impedance analysis (BIA) and 
body-water dilution in lean and overweight women. Skin-fold measurement has been shown 
to have the ability to measure fat mass and fat-free mass within an accuracy of 3-4%
 124
. 
A drawback of skin-fold measurement is that it is difficult to estimate all sources of error, as 
these may vary depending on the make of calliper and the operator taking the measurements. 
Ideally it is recommended that one calliper be used throughout the study. In addition, the 
technique is not recommended for use on subjects who have a BMI in excess of 40, as the 
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skin-fold thickness may be greater than the width of the calliper, making it impossible to take 
accurate measurements. 
1.6.3 Waist-circumference measurement 
The BMI is commonly used for classification of overweight and obesity in men and women. 
However, it does not have the capacity to determine body-fat mass and its distribution. This is 
significant, as body-fat distribution is found to be a powerful predictor for cardiovascular and 
other disease risk factors
 125
. In particular, increased visceral and abdominal adipose tissue has 
been shown to strongly correlate with metabolic and cardiovascular diseases. Waist 
circumference alone has been shown to be more useful and closely associated to central 
obesity than BMI or waist-to-hip ratio
 126
. A study by Booth et al.
 127
, indicated that even self-
reported waist circumference is useful in assessing and monitoring overweight and obesity in 
clinical studies. 
A guideline for management of obesity developed by the National Institute of Health (NIH) 
has also recommended the use of waist circumference and BMI as reliable and easily 
available tools for identifying obesity and monitoring treatments
 122
. Waist-circumference is a 
simple metric to measure as it only requires a measuring tape. Additionally, the measurement 
error has been found to be relatively low compared to other anthropometric methods. 
However, it is not recommended for obese individuals with a BMI > 45, as the abdominal fat 
would be too large for accurate measurements. Height and BMI can be used as alternative 
means of fat prediction for these individuals
 128
. 
1.7. Statement of research question 
Overweight and obesity is a serious and growing global epidemic problem. It significantly 
increases the risk of various diseases such as cardiovascular, diabetes and a number of 
cancers. Successful weight-loss treatment requires long-term lifestyle changes with the aid of 
professional health workers to provide sound clinical advice. This proves to be challenging 
for various individuals and additional aid is often required to assist with the weight-loss 
process. There are numerous prescription weight-loss drugs that are currently approved by 
FDA for their effectiveness and safety, such as Orlistat and Sibutramine. Usage of such drugs 
should be long-term and often weight is regained when the drug is discontinued. Even then, 
their effectiveness is generally marginal. In addition to the challenges of weight loss, medical 
help is seldom sought by the general public, as overweight and obesity is not typically 
regarded as a disease, but is rather associated with sloth and lack of self-control. 
Consequently, the popularity of over-the-counter weight-loss supplements has escalated, as 
they are often advertised as quick-fixes and with a 100% success rate without consumers 
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changing their lifestyle. Aggressive marketing schemes often include convincing testimonials 
and skilful packaging, which may also have an impact on the placebo response. The power of 
advertising can play on consumers’ minds and a placebo effect can be evoked when subjects 
believe in the effectiveness of the drug as suggested by authoritative figures such as the media 
or by testimonials. 
These supplements form a multi-million rand market which is continually expanding as there 
are no regulations in place in South Africa to restrict manufacturers. Manufacturers are also 
not required to conduct methodologically sound efficacy studies before they make the 
supplements available to the consumers.  
The author has no knowledge of previous studies that have been carried out to verify the 
effectiveness and the possible side effects of an over-the-counter weight-loss supplement in 
South Africa, and in particular the influence of advertising and branding on the placebo 
response. In this study we have chosen Bioslim, as it is one of the dominant brands in the 
dietary supplement market, specifically for weight loss. The findings of this study will 
provide some insight into the accuracy of claims made by Bioslim and to record any adverse 
side effects. In addition the results extend current understanding of the impact of intensive 
marketing on placebo effects.  This study can also form the basis for a larger study which 
could include a variety of non-prescription products on the market, thus assisting consumers 
in making a better choice when purchasing a dietary supplement product. Lastly, the study 
may create awareness on the usage of dietary supplements in this country and improve 
vigilance over unsubstantiated products.   
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Chapter 2 
Methodology 
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2.1 Aim 
To investigate whether Bioslim results in greater weight-loss than a placebo, and whether the 
marketing of the Bioslim brand has an influence on the placebo response. 
2.2 Objectives 
1. To evaluate whether there is a significant difference in weight reduction, according to 
Bioslim Once a Day claim, when comparing the active and the placebo groups over a 
period of one month. 
2. To assess whether Bioslim shows a significantly superior effect in reduction of fat 
mass and waist circumference when compared to a placebo, and when other 
anthropometric means are used to determine the efficiency of Bioslim as a weight-
loss drug. 
3. To investigate if subjects follow the guideline, “Only effective when used in 
conjunction with a kilojoule-controlled diet and moderate exercise.” 
4. To document any self-reported side effects of the product. 
2.3 Study Design 
This study was an experimental, randomised, double-blind placebo-controlled prospective 
intervention trial. 
2.3.1 Subjects 
Study population 
The study population was comprised of overweight adults in the Western Cape area. 
Sampling techniques 
All shopping centres that sell Bioslim in the Western Cape area had been considered. 
Kenilworth Centre and Century City were the final two shopping centres that were selected, 
based on the wide range of consumers that they attract and the permission obtained from the 
various centres to carry out the study. The socioeconomic status of the patrons that visited 
these two sites varies from high to low, as consumers from various suburbs visit these two 
shopping centres. In each shopping centre, a stand was set up on various occasions to hand 
out fliers, attached in appendix 1, and to sign up keen participants. 
Advertisements (refer to appendix 1) were also placed in the local community newspaper in 
September and October 2008 inviting volunteers to join the study. These newspapers cover 
areas that surround the two shopping centres. Advertisements were placed in Tygertalk and 
Tabletalk to be distributed in the Goodwood, Parow, Thornton, Milnerton and Tableview 
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area; as well as in The Tatler – serving the Southern suburbs - to cover areas such as 
Mowbray, Observatory, Pinelands, Rondebosch, Newlands, Claremont and Kenilworth. 
All efforts were made to ensure that the implementation of the study mimicked, as closely as 
possible, the manner in which consumers would normally make use of the product. Therefore, 
the study was conducted inside the shopping centres, away from a hospital or academic 
setting in order to minimise external factors that might have influenced the placebo response. 
Subjects who were interested in participating in the study were asked to contact the 
investigator telephonically and to leave their details with the research assistant. The 
investigator then checked the eligibility of the subject. If he/she qualified, arrangements were 
then made to meet the subject in person at the office inside the relevant shopping centre. 
2.3.2Inclusion and exclusion criteria 
The study’s inclusion criteria were: 
 Subject is older than 18 years. 
 Subject has a BMI > 25. 
 Subject had heard of Bioslim before joining the study. 
 Subject had given consent by signing the informed consent form (see Appendix 2). 
 
The study’s exclusion criteria were: 
 Subject is receiving treatment for heart condition. 
 Subject is receiving treatment for diabetes mellitus. 
 Subject is pregnant or breastfeeding. 
 Subject has taken Bioslim before. 
 Subject has a BMI > 40. 
2.4 Methodology 
2.4.1 Preparation of placebo and packaging 
Solaltech, a pharmaceutical company, produced the placebo pill which resembled the real 
Bioslim pill in appearance. Information, such as “Only effective when used in conjunction 
with a kilojoule-controlled diet and moderate exercise”, which appears on the actual Bioslim 
packaging, was also on the No Name packaging, which was stripped of any reference to the 
branded product. 
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The research assistant packaged the pills, placing placebos in either Bioslim or No name 
packages, and active pills in either Bioslim or No Name packages. This resulted in four 
groups of pills. The groups were then colour coded and a subject identification number (ID) 
was randomly assigned to each of the four colours. At the baseline meeting, the investigator 
handed out one of the four formulations to each participating subject according to their 
subject ID, which was based on the order of the subjects’ enrolment. Each subject had an 
equal chance of being placed in any one of the four groups. This process occurred without the 
investigator, or the subjects’ knowledge of the content of the formulation. 
The study subjects were randomised into one of the following four groups: 
Group Red (Placebo branded group) 
The placebo in the Bioslim packaging. 
Group Green (Placebo brandless group) 
The placebo in the No Name packaging. 
Group Yellow (Active branded group) 
The Bioslim formulation in Bioslim packaging. 
Group Orange (Active brandless group) 
The Bioslim formulation in the No Name packaging. 
Table 10: Study groupings 
Packaging Formulation 
Active Bioslim pill Inert placebo pill 
Branded 
packaging 
Group Yellow Group Red 
Brandless  
packaging 
Group Orange Group Green 
 
Groups Green and Orange (brandless packaging) had a menu planner and instructions 
included inside, which simulated the ones found in actual Bioslim packaging. Groups Yellow 
and Red received the actual Bioslim package inserts. 
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The original Bioslim packaging contained 3 bottles with 3 different preparations of the active 
Bioslim pills inside, as well as a meal planner. The same were also found inside the placebo 
packaging, i.e. 3 plain white, similarly sized containers without the Bioslim label and a meal 
planner without any Bioslim logo. The same number of pills was also placed in each bottle to 
ensure that all subjects would take 3 pills for the first 7 days and 2 pills for the next 21 days 
during the trial period. 
The products were given to subjects individually according to the randomisation sheet, 
assigning them to one of the four groups listed above. They were instructed to behave towards 
the product as if they had bought it from the shop themselves. No further instructions were 
given, including dietary instructions and menu planners.  
2.4.2 Anthropometric measurements 
The following measurements were carried out at the baseline and at the follow-up meetings 
according to literature
 129
, and were conducted in an office space inside each of the shopping 
centres. All measurements were repeated three times and the average of the three was used for 
data analysis. 
2.4.2.1 Weight (to the nearest 0.1 kg) 
The subjects were asked to stand still in the middle of the scale without touching anything and 
their body weight equally distributed on both feet. The weight measurement was read to the 
nearest 100g and recorded. The subjects were requested to empty their pockets and remove 
any heavy jewellery, jackets and shoes before standing on the electronic scale. The scale was 
calibrated each day. Height (to the nearest 0.1cm) 
A stadiometer was used to measure the height of subjects. They stood barefoot, with their 
heads in the Frankfort horizontal plane and closely against the stadiometer, their arms resting 
on either side. The subjects inhaled deeply just before each measurement was taken. At each 
repeated measurement, subjects were asked to stand away from the stadiometer, to repeat the 
alignments.  
2.4.2.2 Waist circumference (to the nearest 0.1cm) 
A Hoechstmass 150cm tape measure was used to measure the waist circumference. Subjects 
were asked to stand upright, without clothing and the measurement was taken at the smallest 
circumference between the lower rib cage and the upper hipbone. The tape was tightly 
wrapped around the waist, without compressing the skin and parallel to the floor. Each 
measurement was taken after the end of a normal expiration. 
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2.4.2.3 Mid upper arm circumference (to the nearest 0.1cm) 
The mid upper arm circumference was measured with a two metre anatomical measuring tape 
by locating the midpoint between the scapula and the tip of the elbow. The arm was relaxed 
and resting on the side of the body. The tape was firmly wrapped around the midpoint and 
parallel to the floor. 
2.4.2.4 Skinfold thickness measurements (to the nearest 1mm) 
The triceps, biceps, supra-iliac and subscapular skinfolds were all measured using the 
FatTrack2 electronic calliper. The accuracy of the equipment was ensured by zero calibration 
before each measurement. Subjects were asked to undress and to have only their 
undergarments on. At each site, the thumb and the index finger pinched the subjects one 
centimetre above the actual site and the calliper measured the midpoint of the skinfold, 
without over compressing the skinfold. All measurements were taken on the right half of the 
body. 
2.5 Questionnaire 
At the follow-up session, which was one month after the baseline assessment, a questionnaire 
(see appendix 3) was administered. The questionnaire was compiled by the investigator, the 
study supervisor and co-supervisor. The questionnaire was compiled to investigate subjects’ 
previous experience with other over-the-counter weight-loss drugs, and specifically their 
views on the drugs’ efficacy and if there were any adverse side effects involved. Similar 
questions were asked regarding their experience with Bioslim during the study period. Lastly, 
questions regarding an energy restricted diet and exercise, that were or were not undertaken 
by the subjects during the study period, were also included. Measurement of the physical 
activity level was based on the subjects’ self-reports, as one of the study objectives was to 
investigate whether the subjects did or did not change their physical activity levels and 
whether they attempt lifestyle modification during the study period. 
 Subjects were asked to complete the questionnaire by themselves and to ask for assistance 
from the investigator if they were unsure of any question. These were then coded and entered 
by both the investigator and a research assistant to ensure inter-reliability. 
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2.6 Data and Statistical Analysis 
All data were entered into a Microsoft Excel spread sheet, where the statistician provided 
assistance with the analysis of the data. The computer program, STATISTICS 8.0, was used 
to carry out analysis of the data. 
For ordinal and continuous data, histograms and frequency tables were used to describe the 
data. For continuous data, two-way repeated measures ANOVA were used to analyse the data 
to find associations within the four groups. For nominal data, the maximum likelihood chi-
square statistic was used for analysis. A significance level of 5% was used. 
2.6.1 Body mass index (BMI) 
This was calculated by taking the weight in kilograms divided by the height squared in 
metres. 
2.6.2 Estimation of body fat mass from skinfold measurements 
Body fat mass was calculated by following Durnin and Womersley‘s skinfold prediction 
equation that made use of the sum of four skinfold measurements. Subjects’ gender and age 
were taken into consideration when calculating the body density (Table 11). 
Body fat mass is then calculated as follows: 
Fat mass (kg) = body weight (kg) x [(4.95/D) – 4.5] 
Fat mass % = Fat Mass (kg) / body weight (kg) x 100 
 
Table 11: Equations for determining body density. The four skinfold types are biceps, 
triceps, subscapular and supra-iliac (measured in millimetres)
 121
. 
Age 
(years) 
Men Women 
17-19 1.1620-0.0630 x (log 4 skinfold sites) 1.1549-0.0678 x (log 4 skinfold sites) 
20-29 1.1631-0.0632 x (log 4 skinfold sites) 1.1599-0.0717 x (log 4 skinfold sites) 
30-39 1.1422-0.0544 x (log 4 skinfold sites) 1.1423-0.0632 x (log 4 skinfold sites) 
40-49 1.1620-0.0700 x (log 4 skinfold sites) 1.1333-0.0612 x (log 4 skinfold sites) 
50+ 1.1715-0.0779 x (log 4 skinfold sites) 1.1339-0.0645 x (log 4 skinfold sites) 
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2.7 Ethics and Consent 
Ethics approval was obtained from the University of Stellenbosch Ethics Committee before 
the research project was conducted. An English Participant Information and Consent form 
(refer to appendix 2) was given to all subjects before enrolled into the study. Consent forms in 
other languages were not required, because all participants spoke English. 
All participants entered the study having signed the consent form after the investigator had 
given them a comprehensive oral and written explanation of the study and they were informed 
that participation in the study was entirely voluntary and they were free to decline to 
participate. Declining to participate would not affect participants negatively in any way 
whatsoever. It was the subject’s right to withdraw from the study at any time without 
providing a reason. Any subject that did not follow the study protocol will be removed from 
the study. The information that would be collected would be treated as confidential 
information; if the results were to be published all identities of the participants would remain 
anonymous. 
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Chapter 3 
Results 
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3.1 Demographic Information 
In total, 110 subjects were recruited for the study. However, data was only available for 87 
subjects, as 23 did not complete the study. The drop-out group consisted of 23 participants, of 
whom 8 had been randomised to receive the active drug and 15 to receive the placebo. Drop-
out reasons were: unable to attend the follow-up session (12 subjects); did not complete the 
full course of the product (10 subjects); and one subject who was on the active drug, who 
stopped using it after reporting severe headaches. 
The mean age for the final study group was 40.49 (standard deviation, SD ± 10.05 years) and 
is predominantly white (53%) and female (90%). Table 12 describes the demographic 
characteristics of the study population.  
Table 12: Demographic characteristics of the study population 
Subject Characteristics 
Female 
N = 78 (90%) 
Male 
N = 9 (10%) 
Total Subject 
N=87 
AGE  
18 TO 29 YEARS 9 3 11 (13%) 
30 TO 39 YEARS 28 1 29 (33%) 
40 TO 49 YEARS 25 2 27 (31%) 
50 TO 59 YEARS 15 2 17 (21%) 
60 + 1 1 2 (2%) 
Ethnicity   
White 40 6 46 (53%) 
Black 7 0 7 (8%) 
Coloured  30 3 25 (38%) 
Indian 1 0 1 (1%) 
4 study groups  
Yellow 
(Active drug with Bioslim packaging) 
21 5 26 (30%) 
Orange 
(Active drug with No Name packaging) 
20 2 22 (25%) 
Green 
(Placebo with No Name packaging) 
21 1 22 (25%) 
Red 
(Placebo with Bioslim packaging)  
16 1 17 (20%) 
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3.2 Anthropometry 
3.2.1 Total study group (n = 87) 
The baseline and follow-up anthropometric characters for the total study population are 
shown in Table 13. The mean BMI for the population at baseline was 31.90 kg/m
2
 with male 
mean BMI = 32.38 kg/m
2
 and female mean BMI = 31.84 kg/m
2
. Both are classified as class  
obesity. Fat mass percentage means at baseline for the male group were 28% and 38% for the 
female group. These are considerably greater than the recommended levels (25% for male and 
35% for female) and are considered as obese, based on the relationship between BMI and fat 
mass percentage reported by WHO
 130
 (there is no exact cut off percentage available for body 
fat mass percentage derived from direct measures). 
The same was found for the mean waist circumference at baseline, where the male group had 
a mean of 108.21cm and the female, 99.28cm, both groups exceeding their individual gender 
categories’ recommendation of 102cm for men and 88cm for women according to the 
Practical Guide by the National Institute of Health (NIH)
 104
. 
At the follow-up measurement, none of the measured anthropometric variables had changed 
significantly compared to the baseline for the total population.  
None of the anthropometric measures had any significant changes amongst the female 
subjects when comparing baseline to follow-up measurements. The same was true of the male 
subjects apart from the fat mass percentage which had a significant change (p = 0.03). 
The repeated measures analysis of variance test showed that in this study, that males and 
females behave differently from baseline to follow-up (p = 0.02): females had a marginal 
weight-loss of 0.014 kg, whereas  males gained 1.03 kg. 
There was no significant difference in anthropometric characteristics such as BMI (p = 0.48), 
waist circumference (p = 0.89) and fat mass percentage (p = 0.43) at baseline between the 
four study groups. Any changes between groups at follow-up could not be ascribed to 
differences in anthropometrical characteristics at baseline. 
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3.2.2 Total study group analysed by active or placebo ingredients 
In this section, because there was no significant difference in demographic characteristics 
such as age (p = 0.58) and gender (p = 0.35) at baseline between the study groups, female and 
male data were analysed together. 
When the total study group sample was analysed, based on the drug treatment group they 
were allocated, namely active or placebo, there was no significant weight loss from baseline 
to follow-up group for either group. The active drug group (N = 48) had a mean weight loss 
of -0.23kg (SD = 0.21) and placebo group (N = 39) a gain in weight of 0.26 kg (SD = 0.24); 
no significant difference was found (p = 0.13). The mean fat mass difference between 
baseline and follow-up measurement for active and placebo group was 0.08 kg (SD = 0.21) 
and -0.11kg (SD = 0.23) respectively; similarly, no significance was found (p = 0.55). Figure 
1 shows that the follow-up measurements did not change significantly from the baseline 
measurements. This applies to both weight and fat mass measurements. 
Table 13: Anthropometric data for active and placebo treatment groups 
*Repeated Measures Analysis of Variance test was carried out. 
Anthropometri
c data 
Baseline Follow up p –
value* 
Active Placebo Total Active Placebo Total  
(N = 48) (N = 39) (N = 87) (N = 48) (N = 39) (N = 87) 
Weight [kg] 
(SD) 
86.10 
(13.07) 
82.32 
(10.39) 
84.40 
(12.11) 
85.85 
(13.23) 
82.58 
(10.42) 
84.39 
(12.18) 
p = 
0.13 
Height [m]  
(SD) 
1.63  
(0.07) 
1.62 
(0.06) 
1.63 
(0.07) 
1.63 
(0.07) 
1.62 
(0.06) 
1.63 
(0.07) 
- 
Body Mass 
Index [kg/m
2
] 
(SD) 
32.22 
(4.05) 
31.51 
(3.64) 
31.90 
(3.91) 
32.12 
(4.06) 
31.61 
(3.67) 
31.89 
(3.92) 
p = 
0.10 
Mid upper arm 
circumference 
[mm] (SD) 
33.92 
(2.65) 
32.39 
(3.59) 
33.24 
(3.18) 
33.75 
(2.6) 
32.49 
(2.83) 
33.19 
(2.80) 
p = 
0.30 
Estimated Fat 
mass [kg] (SD) 
31.68 
(6.47) 
31.20 
(5.82) 
31.46 
(6.23) 
31.75 
(6.55) 
31.11 
(5.66) 
31.46 
(6.20) 
p = 
0.55 
Estimated Fat 
mass [%] (SD) 
40.93 
(6.24) 
37.82 
(4.67) 
37.25 
(4.69) 
37.02 
(5.02) 
37.66 
(4.6) 
37.31 
(4.85) 
p = 
0.21 
Waist 
circumference 
[cm] (SD) 
100.16 
(9.82) 
100.25 
(7.05) 
100.2 
(8.74) 
99.95 
(10.38) 
98.77 
(7.59) 
99.42 
(9.31) 
p = 
0.11 
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Figure 1: Baseline and follow-up means for weight and fat mass 
 
3.2.3 Total study group analysed by packaging presentation 
Table 14 illustrates the anthropometric data of the 2 groups divided according to the type of 
packaging the product was dispensed in. Baseline anthropometric data changed minimally 
when compared to the follow up measurement, this was found for both the Bioslim and No 
Name packaging groups, and the difference between the baseline and follow up 
measurements was determined. No significant difference was seen between the mean weight 
difference of the Bioslim packaging group (mean difference = 0.11kg, SD = 0.23), and the 
Bioslim dispensed in No Name packaging group (mean difference = 0.14kg, SD = 0.22), (p = 
0.43). A mean difference for Fat mass of -0.16kg (SD = 0.22) and 0.13kg (SD = 0.22) was 
recorded for the Bioslim and No Name packaging respectively and it was found not 
significantly different (p = 0.35). 
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Table 14: Anthropometric data for various packaging groups 
*Repeated Measures Analysis of Variance test was carried out. 
Anthropometric 
data 
Baseline Follow up  
Bioslim 
Packa 
ging 
No 
Name 
Packa- 
ging 
Total 
Bioslim 
Packa- 
ging 
No 
Name 
Packa- 
ging 
Total 
p – 
value* 
(N = 43) (N = 44) (N = 87) (N = 43) (N = 44) (N = 87)  
Weight [kg] (SD) 
85.72 
(11.95) 
83.11 
(12.13) 
84.40 
(12.11) 
85.54 
(11.91) 
83.26 
(12.34) 
84.39 
(12.18) 
p = 0.43 
Height [M] (SD) 
1.63 
(0.07) 
1.62 
(0.07) 
1.63 
(0.07) 
1.63 
(0.07) 
1.62 
(0.07) 
1.63 
(0.07) 
- 
Body Mass Index 
[kg/m
2
] (SD) 
32.09 
(3.95) 
31.17 
(3.09) 
31.90 
(3.91) 
32.03 
(3.96) 
31.76 
(3.93) 
31.8 
9(3.92) 
p = 0.35 
Mid upper arm 
circumference 
[mm] (SD) 
33.37 
(2.63) 
33.10 
(3.67) 
33.24 
(3.18) 
33.22 
(2.55) 
33.16 
(3.05) 
33.19 
(2.80) 
p = 0.44 
Estimated Fat 
mass [kg] (SD) 
31.47 
(6.64) 
31.46 
(5.88) 
31.46 
(6.23) 
31.34 
(6.48) 
31.59 
(6.00) 
31.46 
(6.20) 
p = 0.35 
Estimated Fat 
mass [%] (SD) 
36.68 
(5.33) 
37.8 
(4.00) 
37.25 
(4.69) 
36.67 
(5.37) 
37.93 
(4.32) 
37.31 
(4.85) 
p = 0.69 
Waist 
circumference 
[cm] (SD) 
99.59 
(7.49) 
100.8 
(9.86) 
100.2 
(8.74) 
99.27 
(9.13) 
99.58 
(9.58) 
99.42 
(9.31) 
p = 0.24 
3.2.4 Total study group analysed by combining the effect of packaging and 
ingredients. 
Anthropometric data were analysed according to the 4 groups that subjects were randomly 
assigned to at the start of the trial. Each group was influenced by the combination of two 
variables, namely packaging and ingredient as listed in Table 15.  
Figure 2 represents the difference in anthropometric measurments between baseline and 
follow-up for the 4 treatment groups. No significant difference between the four groups in 
weight (kg), fat mass (kg) and waist circumference was found. Two groups received the 
active ingredient (yellow and orange) and two groups received the placebo (green and red) 
and no trend was found between the groups. Only the yellow group had a mean loss in weight 
(-0.45kg), the remainder had either no weight loss or an increase in weight. Fat mass showed 
a relatively minuscule change and only the red group achieved a loss in fat mass (-0.30kg). 
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Contradictory to the weight difference finding, all groups had a mean waist circumference 
loss except for the yellow group (0.54cm). 
Table 15: Anthropometric means and standard deviations for the 4 study groups 
4 Study Groups 
Weight difference 
(kg) 
(p = 0.30) 
Fat mass 
difference (kg) 
(p = 0.76) 
Waist 
circumference 
difference (cm) 
(p = 0.15) 
Yellow 
(Active drug with Bioslim 
packaging) 
-0.45 (1.67) -0.02 (1.36) 0.54 (4.84) 
Orange 
(Active drug with No Name 
packaging) 
0 (1.44) 0.18 (1.56) -1.09 (2.49) 
Green 
(Placebo with No Name 
packaging) 
1.29 (1.32) 0.08 (1.27) -1.36 (2.63) 
Red 
(Placebo with Bioslim packaging)  
0.24 (1.35) -0.30 (1.36) -1.64 (2.97) 
 
Table 15 shows anthropometric means and standard deviations for the 4 study groups, where 
weight, fat mass and waist circumference differences were derived from taking the value at 
follow-up less the baseline value. All negative signs indicate a loss in mass or centimetres at 
the end of the study period. No statistical significance was found between the 4 treatment 
groups, as weight difference (p = 0.30), fat mass difference (p = 0.76) and waist 
circumference (p = 0.15) were all greater than (p = 0.05). 
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Figure 2: The difference in anthropometric measurements between baseline and   
follow-up 
Yellow = Active drug, Bioslim packaging 
Orange = Active drug, No Name packaging 
Green = Placebo, No Name packaging 
Red = Placebo, Bioslim packaging 
3.3 Questionnaire 
3.3.1 Subjects’ perception of the effectiveness of Bioslim 
As many as 72% of the subjects were confident of the effectiveness of Bioslim at the start of 
the trial. This confidence seemed to have been engendered by marketing, which entails 
packaging, testimonials and advertising, since it was the most common factor leading subjects 
to believe in Bioslim’s effectiveness. Figure 3 illustrates the factors that influenced subjects’ 
perception, which prompted them to believe in the efficacy of Bioslim, without having prior 
experience with usage of the product. Marketing was definitely the domineering factor that 
influenced subjects’ perception of the efficacy of the product, with 59% of the subjects 
agreeing that Bioslim was effective, based simply on their marketing. This finding was 
further confirmed by the significant difference found between the Bioslim packaging and No 
Name packaging group, when comparing non-believers to believers (chi-square test, p = 
0.04). 
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Figure 3: Factors influencing subjects' perception of the efficacy of Bioslim 
3.3.2 Consumers’ satisfaction with the usage of weight-loss products 
In this study, 42 (48%) subjects reported having used other weight-loss drugs previously (see 
Figure 4). The most commonly used products included Leanor (n = 6) and Herbalife (n = 6). 
Out of the 42 subjects who had previous experience, only 17 (40%) subjects were satisfied 
with the result. Here, satisfaction is defined as the product meeting the subjects’ expectation 
and having the desired effect, namely weight loss. Similar results were found regarding 
subjects’ experience with Bioslim in the study, as only 33% (n = 29) reported being satisfied, 
with the remaining 67% unsatisfied. Of this group, 83% (n = 24) reported being unsatisfied 
because of their failure to detect any significant weight loss. 
 
Figure 4: Weight-loss products used by subjects before joining the study 
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3.3.3 Exercise 
Assessment of the questionnaire comparing the Bioslim and No Name packaging group 
shows that packaging did not promote subjects’ inclination to exercise (chi-Square test, p = 
0.59), as 23 subjects from the Bioslim packaging group and 21 subjects from the No Name 
packaging group answered yes to exercise during the trial. In addition, the mean exercise time 
for those who did exercise was 176.96 minutes (SD = 21.15) in the Bioslim packaging group 
and 135.48 minutes (SD = 110.04) in the No Name packaging group. Although the fat mass 
reduction was clinically minimal, the length of time spent on exercise by the total study group 
correlated significantly with fat mass reduction (r = -0.31, p = 0.004). Furthermore, when data 
was analysed separately as active (n = 48) and placebo (n = 39) groups, the active drug group 
(see Figure 5) reveals an even stronger correlation (r = -0.45, p = 0.0012), while the placebo 
drug group showed an insignificant, weak correlation (r = -0.05 p = 0.77). The same was not 
reflected in weight loss (r = -0.007, p = 0.95) and waist circumference difference (r = -0.08, p 
= 0.45), where there was no significant correlation to length of exercise, despite weight 
difference, and fat mass difference being significantly correlated (r = 0.48, p = 0.00).
Scatterplot of FM difference against Total time exercised
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Figure 5: Fat mass difference against total time exercised (minutes). 
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3.3.4 Diet 
Fifty-four out of 87 (62%) subjects did change the way they ate during the study to try and 
lose weight. This did not have a significant impact on weight (p = 0.31), fat mass (p = 0.95) 
or waist circumference (p = 0.31). The subjects’ decision to change their diet was not 
influenced by the packaging (p = 0.89), nor the disclaimer/instruction on the packaging, nor 
the type of pills (p = 0.42) that were administered. 
The most common way in which subjects’ reported changing their diet was to cut down 
carbohydrate intake (see Figure 6). This is compared to other macronutrients, where 
increasing protein consumption was mentioned only once and reducing fat intake was 
mentioned 10 times. 
All subjects were provided with the same menu plan, as found in the Bioslim packaging, but 
only 34 subjects made use of this plan and only one out of the 34 claimed to have succeeded 
in following the diet, defaulting less than 4 days during the one month study period. 
 
 
Figure 6: Ways in which subjects claim to have changed their diet during the trial 
Participants mentioned, “decrease in carbohydrate intake” (n = 16) as the most frequent 
response, “increased water intake” (n = 13), and “less take-out”, “decrease in fat intake” and 
“decreased portion size” (n = 10). 
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3.3.5 Side effects 
Nine of the 87 (10.34%) subjects reported various side effects: heart palpitation (n= 1), dry 
mouth (n = 2), increased appetite (n = 1), constipation (n = 3), nausea (n = 1), gaseous 
stomach (n = 1) and fatigue (n = 1). Three out of the 9 subjects who reported side effects were 
receiving active pills. Table 16 contains a list of side effects reported by subjects and their 
frequency, including the types of packaging and ingredients each subject was receiving. In 
total 3 out of 9 (33%) subjects who claimed to experience some side effects, were on active 
ingredients and 5 out of 9 (66%) subjects received Bioslim packaging. The individual who 
had experienced heart palpitations was on active drug and No Name packaging. 
 
Table 16: List of side effects reported by subjects and their frequency, based on the type 
of packaging and ingredients each subject was receiving. 
Side effect 
Number of 
subjects 
affected 
Pill type Packaging type 
Active Placebo Bioslim No Name 
Heart palpitations 1 1 0 0 1 
Dry Mouth 2 0 2 1 1 
Increased appetite 1 1 0 1 0 
Constipation 3 0 3 1 2 
Gaseous stomach 1 1 0 1 0 
Nausea 1 0 1 1 0 
Fatigue  1 0 1 0 1 
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Chapter 4 
Discussion 
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4.1 Efficacy of Bioslim as a weight-loss dietary supplement 
The efficacy of Bioslim was evaluated by comparing the subjects receiving Bioslim (the 
active treatment group) to the placebo group, to ascertain if there were any significant 
differences in anthropometric changes from baseline to follow-up measurement. The 
intervention period was chosen as one month, as this is the period over which Bioslim 
advertised efficacy. The results show that although the active treatment group subjects did 
loss a marginal amount of weight, and the placebo group had a slight increase in weight over 
a period of one month, the difference in weight changes was not significant (p = 13). 
 Similar outcomes were observed for fat mass and waist circumference; none of the 
anthropometric measures revealed any significant differences between the active and placebo 
groups. Female and male subjects were not analysed separately, as at baseline it was found 
that the study groups were not significantly different to each other with regard to both 
demographic and anthropometric characteristics. In other words, male and female subjects 
were equally distributed between study groups. 
The lack of efficacy of Bioslim as a weight-loss dietary supplement found in this study is 
supported by previous reviews on dietary supplements which are used for anti-obesity 
purposes, in which no supplement was found to be effective in reducing body weight
 131, 132, 
133
. 
The two main ingredients in Bioslim are pyruvate and Citrus aurantium.  
The study by Pittler et al.
 133
, which tested pyruvate on its own, at a daily dose of 6g and 
which included exercise and an energy restricted diet for the 6 week trial period, found that 
pyruvate did not have an effect on weight reduction when compared to a placebo group. 
Bioslim contains only one thirtieth of that dose; in addition exercise and diet were not 
compulsory for this study.  
Trials investigating the efficacy of Citrus aurantium, made use of Citrus aurantium at a much 
higher dosage than the 230mg found in Bioslim or ephedrine was incorporated as one of the 
active ingredients to further increase the adrenergic stimulatory effect
 69, 77, 78, 79
.  
The equivalent amount of synephrine alkaloid found in Citrus aurantium from these trials is 
5-14mg per day. It was noted by Haaz et al.
 61
 that no serious adverse events were reported at 
this dose, but that it may be too low to serve as an effective weight-loss supplement, unless 
used in conjunction with ephedrine. According to Jones et al.
 77
 1 mg/kg/day is potentially a 
safe and efficacious dose of synephrine alkaloid, taking into consideration that 1000 mg per 
Stellenbosch University http://scholar.sun.ac.za
57 
 
day is the minimal lethal dose for an adult, according to Martindale: The Complete Drug 
Reference
 134
.  The dose frequency of Bioslim (once a day) may also be the reason for the lack 
of efficacy found in this study. Synephrine alkaloid is readily absorbed after oral ingestion 
and reaches plasma peak in 1-2 hours, its half-life being 2-3 hours. This would suggest that, a 
regimen of a dose of three times a day would be required for it to be effective
 135
. 
In conclusion, when investigating the two key active ingredients of Bioslim, pyruvate and 
Citrus aurantium, it was found that previous studies did not support efficacy in weight loss. 
The results of this study confirm these findings. Pyruvate and Citrus aurantium, the active 
ingredients of Bioslim, did not have any significant weight-loss effect in the active-ingredient 
group when compared to the placebo group. Furthermore, even if these two ingredients are 
potent weight-loss enhancers, the dose and dosing frequency of Bioslim is neither comparable 
nor sufficient to induce any weight loss. 
4.2 Consumers’ confidence in the weight loss product 
Seventy-two percent of the subjects considered Bioslim to be an effective dietary supplement 
for weight loss at baseline, demonstrating significant confidence in the product. This finding 
correlates with the results of a US national survey, which showed that 63% of subjects who 
used dietary supplements believed that they are effective weight-loss products. Furthermore, 
49% believed that all dietary supplements are tested by a government agency for efficacy
 136
. 
This is clearly a misconception, as in both the USA and SA, no regulations are in place to 
monitor the efficacy or the safety of dietary supplements currently available to the general 
consumer. The dietary supplement market is fast-growing and lucrative. Consumers spent 
R889 million in 2003 (the most recent data available) on products whose efficacy has not 
been proven, and more importantly, whose safety profile is unknown
 137
. 
Clinical guidelines recommend that successful weight loss and maintenance require physical 
activity and lifestyle changes
 64
. However, such interventions are difficult to follow, as they 
require much effort and discipline. As a consequence, consumers are in search of alternate 
quick-fix methods, which in turn fuel the dietary supplement market, since most products 
advertise to accomplish just that. These products are available to the consumer without the 
need for a prescription, making them easily accessible. They are aggressively advertised, and 
furthermore, they are often cheaper than prescription weight-loss drugs and do not require the 
payment of consultation fees to a doctor. The US national survey also found that 67% of 
subjects do not seek weight-loss assistance from a doctor and 69% admit that they fail to 
report their concomitant use of dietary supplements to their doctors
 136
. This is worrisome, as 
obesity is regarded as a disease, and like all other chronic diseases of lifestyle, it is associated 
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with “hidden” secondary sequelae. The assistance of professional health carers is vital to 
ensure efficacy and safety of weight loss attempts. 
In this study, marketing was one of the most compelling reasons for believing in the efficacy 
of Bioslim, as 59% who were confident in Bioslim’s efficacy said their belief was based on 
Bioslim’s marketing material such as testimonials shown on television advertisements or the 
attractive packaging. One of the inclusion criteria was that all subjects were required to have 
heard of Bioslim before entering the study, either via word of mouth or by encountering 
Bioslim marketing materials, but not to have actually used the product. This does not mean 
that the reason people joined the trial was because of their interest in Bioslim, as no mention 
of Bioslim appeared in the local newspaper advertisement recruiting subjects. To further 
illustrate the power of marketing on consumer perception, it was found that subjects who 
received the branded package in this study had a significantly greater confidence in the 
efficacy of Bioslim when compared to subjects who received No Name packaging. 
Bioslim’s aggressive marketing schemes often include testimonials to illustrate the product’s 
efficacy rather than the use of sound clinical trials. This study’s results indicate that 
marketing is, without a doubt, a useful method of enticing the consumers to believe in the 
efficacy of the product, which in turn, leads to the purchase of the product. An increase in 
sales also leads to increased funding to fuel marketing schemes, as can be seen by the 189% 
growth in the amount spent on advertising dietary supplements in South Africa in 2001, a 
total of USD 944 million, reaching USD 2.7 billion in 2005
 138
. 
In a study by Pillitteri et al.
 136
, the use of dietary supplements for weight loss was found to be 
more common in females, younger adults, individuals with a lower educational level and 
subjects with lower incomes. In this study, more females than males enrolled in the study 
which could be anticipated, since previous studies have shown that weight-loss products 
attract more attention from South African females, as they are more concerned with body 
image
 35
. What is concerning, is that lower income individuals could possibly spend more 
money on weight-loss products, with little efficacy, because of the media influence, rather 
than buying healthy, nutritious food and receiving individualised health advice concerning 
weight-loss from professionals such as dieticians. 
4.2.1 The effect of marketing on the placebo effect and the possible enhancement 
of Bioslim’s efficacy 
In this study, subjects were randomised to receive one of the four treatments. Each group was 
influenced by a combination of two variables: packaging (either No Name or Bioslim 
packaging) and the pill components (either with the active ingredient or a placebo).  It was 
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found that there were no significant differences between the groups when comparing weight, 
fat mass and waist circumference changes after the 4 week trial period. It was originally 
postulated that due to Bioslim’s aggressive weight-loss campaign, its intense advertising 
would foster a greater false expectation of effortless weight loss, without much change in diet 
or in exercise regime, than an unbranded placebo would. This study postulated that 
advertising may increase the placebo effect and evoke physiological reactions, where subjects 
may subconsciously try harder to exercise more and eat more healthily. As was shown with 
painkillers, when volunteers took an inert substance and believed that they had been given a 
potent painkiller, some of the volunteers naturally released opioids in the expectation of pain 
relief
 113
. However, in this study, marketing did not have a significant impact on the placebo 
effect. One explanation is that the subjects’ repeated failure with previous weight-loss 
attempts, using dietary supplements, may have resulted in lower expectations, therefore 
reducing this possible influence. Sixty percent of subjects who had previous experience with 
other weight-loss supplements were dissatisfied with their results and found that these weight-
loss supplements made no difference to weight loss. Therefore, even though all of the subjects 
in this trial had no previous experience with Bioslim, they had shown great confidence in its 
efficacy, so that one might have expected a noticeable increased placebo effect, but this was 
not evident. The level of expectation may have been diminished by a lack of conviction in the 
efficacy of weight-loss supplements in general. 
4.3 The potential dangers of using Bioslim 
4.3.1 Adverse side effects 
Nine subjects (10%) reported adverse side effects whilst participating in the study, including 
nausea, constipation, dry mouth, and heart palpitations whilst participating in the study. These 
are commonly associated with the use of ephedrine and synephrine alkaloids
 87
. There was no 
significant difference between the active and placebo group concerning the occurrence of 
reported adverse events. It should be noted however, that one subject from the active group 
withdrew from the study because of heart palpitations. 
4.3.2 Quality and safety of dietary supplement products 
Dietary supplements are often perceived to be safe because they are made from natural herbal 
ingredients. This was illustrated by a survey that investigated the use of dietary supplements 
by the general consumer. Results from the survey showed that a third of the interviewed 
subjects believed dietary supplements are safer to use than prescription drugs
 136
. This is not 
always true as Ephedra, a once popular ingredient in weight-loss supplements and now a 
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banned substance, is known to raise blood pressure and can be harmful, particularly to people 
with existing hypertension
 72
. Hypertension is also common with weight-loss drug users, as it 
is frequently found in overweight or obese subjects.  
The risk of using dietary supplements is often underestimated, in addition the product quality 
and accuracy of labelling are also overlooked. An example of this was illustrated in a study 
by Coffey et al.
 139
 on a dietary supplement that contains ephedrine. They found that the stated 
quantity of each ingredient was less than half of the actual quantity when compared by two 
independent lab analyses of the supplement. This shows that manufacturing control of the 
product is not as rigorous as one would expect it to be and the quality of the tests conducted 
on these products is then in question. One study examined 20 ephedra-containing dietary 
supplements, using liquid chromatography to investigate the actual content versus the label 
claims. It was found that half of the products showed a discrepancy in excess of 20% between 
the label and the actual alkaloid content. Not only did the content not match the label 
information, but it was also found that two lots of the same product were also inconsistent in 
ingredients. One product did not even contain ephedra alkaloid
 140
. This poses a serious 
concern as the amount in the supplement may reach the toxicity level, contradictory to the 
level stated on the label, further highlighting the risk of using dietary supplements that are 
unregulated. 
In 2007, the FDA established Good Manufacturing Practices (GMPs) for the dietary 
supplement industry. This is a process that the manufacturers have to adhere to so that the 
products are safe, effective and non-toxic. For a manufacturer to fully comply with GMPs, 
there are certain processes to follow such as quality control of the product, supply and 
preparation of the raw material and packaging and labelling of the products. Adherence to 
GMPs needs to be substantiated by third party audits. There are a few elements that need to 
be tested to ensure good compliance; these are identifying the materials, product stability over 
time, contaminant testing and potency assays
 141
. These elements were not tested in this study, 
as it was not an objective of the study to quantify the ingredients of Bioslim pills or to 
determine whether the content matched the labelling. 
In South Africa, any dietary supplements which make any medicinal claims and meet the 
definition of a medicine must be licensed by the MCC for current good manufacturing 
processes as part of the registration process. According to the Medicines and Related 
Substance control act, 1965
 96
, Bioslim is regarded as a medicine and yet, according to the 
author’s understanding, Bioslim is not licensed by the MCC nor required to comply with 
good manufacturing processes. 
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4.4 Physical activity 
4.4.1 Correlation between exercise and body composition. 
Although other factors play a role in the gaining or losing of weight, simplistically it can be 
considered as a result of the difference between energy intake and energy expenditure. A 
negative energy balance, due to higher energy expenditure, such as an increase in physical 
activity, will result in loss of weight
 142
. Subjects in this study demonstrated that the amount 
of time spent on exercising was significantly correlated to the amount of fat mass lost (r = - 
0.45, p = 0.0012). This correlation was only found in the active group. In the placebo group, 
the same correlation was not found between time spent on exercising to fat mass lost (r = -
0.05, p = 0.77). Therefore, subjects who are on Bioslim may lose more fat mass when they 
exercise. However none of the subjects in this study lost a significant amount of fat mass after 
taking the product for one month. 
Interestingly, even though weight and fat mass were significantly correlated in the active 
group (r = 048, p = 0.00), weight and time spent on exercise were not significantly correlated 
in the active or placebo group. A systematic review by Kay et al.
 143 
explains that physical 
exercise can change body composition without the reduction of body weight. As exercise 
improves body composition by reducing fat mass and increasing fat free mass, this factor is 
more pertinent to reducing metabolic and cardiovascular health risks than actual weight loss
 
143
. 
Furthermore, when examining the effect of packaging or marketing on the subjects’ 
behaviour, it was found that whether subjects received the Bioslim packaging or the No Name 
packaging, made no difference to the total time they spent exercising. Therefore, the actual 
Bioslim packaging does not motivate subjects to exercise harder and as a result lose more 
weight.  Although a high percentage (72%) of subjects in the group who received Bioslim 
packaging, were confident in the effectiveness of Bioslim, it appears that their confidence in 
the product, prompted by marketing, did not motivate them to improve their lifestyle choices 
to enhance weight loss. Subjects relied purely on the product itself, and did not consider their 
own lifestyle changes as necessary for contributing and encouraging weight loss, even though 
the package assertion says, “Only effective when used in conjunction with a kilojoule-
controlled diet and moderate exercise”. One possible explanation is that the advertisement for 
from Bioslim persuasively suggests that the product itself is so effective that consumers do 
not need to restrict their dietary intake or increase their physical activity. 
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4.4.2 Weight maintenance and exercise 
Exercise plays a pivotal role in the treatment of those who are overweight and obese, as well 
as preventing weight regain after successful weight loss
131
. However, more and more people 
are adopting a sedentary lifestyle, relying heavily on motor vehicle transport and 
entertainment that does not require physical activity. Measurement of physical activity faces 
various challenges, and as a result there is a lack of quality data correlating the relationship 
between physical activity and obesity. Self-reporting methods are often adopted because of 
their convenience, instead of the use of objective measurements, which often provide a more 
realistic perspective. Physical activity assessment is also multifaceted; one needs to consider 
intensity, frequency, duration, and the type of activity that took place. Even in the absence of 
direct evidence to support this statement, there are observational data to indicate the 
importance of exercise in weight-loss
 144
. 
A study by Steyn et al.
 145
, investigating chronic diseases of lifestyle in South Africa, found 
that dramatic lifestyle changes occur when rural dwellers move to urban areas. It was found 
that the change in their environment reduced their physical activity level and the transition in 
nutritional intake was associated with the increased prevalence of overweight and obesity. In 
rural areas physical activity is part of life, and since motor vehicle transport is rarely 
available, villagers will walk to school and to health facilities which are often far away. 
However, as transport has become more readily available and television and electric 
appliances are now regularly found in homes, more time is spent on sedentary activities
 145
. 
The decline in physical activity levels is one of the major factors contributing to the rising 
obesity epidemic, impacting not only the developed, but also the developing world, including 
South Africa
 146
. 
It has been shown that physical inactivity is associated with an increased risk of mortality and 
morbidity resulting in coronary heart disease, stroke, diabetes, cancer and mental illness such 
as depression
 147
. In contrast, exercise in overweight and obese individuals substantially 
reduces disease risk and healthcare costs. It is possible to be overweight and physically fit at 
the same time, reducing morbidity risk; exercising then is not only for the purpose of weight 
loss
 148
. 
The pertinent question is, exactly how much physical activity is required for the prevention of 
weight gain or weight regain? The main guideline recommendation, according to the US 
Center for Disease Control and Prevention
 146
, is that sedentary adults should accumulate 30 
minutes or more of moderate-intensity physical activity every day of the week. This 
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recommendation is targeted for the improvement of health by increasing cardiovascular 
fitness. However for prevention of weight gain or regain, the US Institute of Medicine (IOM) 
recommends 60 minutes of moderate-intensity physical activity on a daily basis
 149
. In a 
prospective study by Shoeller et al.
 150
, using DLW (double labelled water), it was found that 
one year after obese subjects lost their weight, those who had a physical activity level (PAL) 
of 1.75 (where PAL of 1 indicates resting metabolism) regained the least amount of weight. A 
physical activity level such as this translates into 60 minutes of moderate intensity activity, in 
line with IOM’s recommendation. 
Physical activity alone, without energy restriction, has been shown to induce fat loss and an 
increase in lean body mass, rather than a total weight reduction
 151
. However, when it comes 
to weight maintenance, over 50% of individuals who lose weight purely on energy restriction, 
regain the weight that was lost. This could be because dietary restrictions are difficult to 
sustain over time and such deprivation can result in a reduced resting metabolism to counter 
the effect of reduced energy intake
 142
. Donnelly et al.
 142
 further state that exercise is one of 
the greatest predictors for weight maintenance for those who have lost weight previously. 
4.5 Dietary intake 
Sixty-two per cent of the subjects in this trial attempted dieting by either increasing their fibre 
intake, cutting back on carbohydrates, minimizing take-aways or by reducing portion sizes. 
This change in dietary behaviour does not seem to have been influenced by the packaging of 
the product they received, as there was no significant difference found between “No Name” 
packaging and “Bioslim” packaging groups, when comparing subjects’ dieting attempts. The 
effect of dieting did not have any impact on any of the anthropometric measurements either. It 
is interesting to note that only 62% of subjects decided to follow the guideline, “Only 
effective when used in conjunction with a kilojoule-controlled diet and moderate exercise” 
(which could be found in small print on all of the products given out regardless of which 
packaging subjects received). The MCC stipulates that this guideline is mandatory for all 
manufacturers selling weight-loss supplements. However, Bioslim marketing material which 
is often broadcast on TV can be seen to contradict this guideline for making life-style 
changes, leading the consumers to often ignore the “fine” print and to rely on the product 
alone for weight loss. These adverts strongly insinuate that diet and exercise are not required 
and that the consumers can rely on Bioslim’s efficacy alone. 
When asked what dietary changes subjects made, “cutting back carbs” was the most frequent 
response. Correlating to USA data, a very low carbohydrate diet and a high lean protein 
intake is a popular method of attempting to lose weight. A diet such as this recommends that 
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the majority of energy should be obtained from protein and fat sources, while carbohydrate 
intake should be kept to a minimum. Thus the dietary intake of carbohydrates no longer 
supports normal glycolysis, i.e. using glucose as the normal substrate to provide fuel for the 
body. When the glycogen or glucose stores are depleted, the body uses ketones, the product 
from lipolysis, as its main source of energy. 
There are different variations of the low-carbohydrate diet, but it is generally defined as a diet 
allowing a maximum intake of 30-60g of carbohydrates per day without any restriction on 
energy intake. Some promote increased intake of fatty foods such as bacon, fried eggs and 
steak, as well as the avoidance of cereal, fresh fruit and starchy vegetables
 152
. Other low-
carbohydrate diets advocate lean protein sources and up to 100g/day low GI starches. These 
diets are in contrast to prudent dietary recommendations by health authorities such as the 
American Diabetes Association (ADA) diet, which advocates that less than 30% of daily total 
energy should be from fat, 50-55% from carbohydrates and 10 - 20% from protein
 153
.In 
addition, South African prudent dietary guidelines recommend that 50 - 60% of total energy 
should be from carbohydrates, 30% or less from fat, and protein should constitute 12 - 15% of 
total energy intake
 154
. Restricting carbohydrate intake will shift the total energy distribution 
between the macronutrients, and as a result most energy intake will be from fat and protein. 
Increasing fat intake to compensate for the low carbohydrate energy sources increases the risk 
of developing an unfavourable lipid profile and the risk of micronutrient deficiencies
 152
. 
A meta-analysis of randomised controlled trials compared low-carbohydrate diets to low-fat 
diets and found that although low-carbohydrate diets are a popular alternative, they show no 
additional benefit in weight loss effect over low-fat diets after one year
 155
. A study by Foster 
et al.
 156
 found that a low-carbohydrate diet was more effective for weight loss after 3 to 6 
months than a low-fat diet, but no difference was found after one year.  In addition, most 
trials are too short to accurately examine the cardiovascular morbidity or mortality. When 
surrogate markers such as LDL-cholesterol, HDL-cholesterol and triglyceride levels were 
measured to predict cardiovascular risks, it was found that low-carbohydrate diets increased 
the LDL-cholesterol level, but favourable changes were found in the other two markers. It is 
unclear whether the favourable changes in HDL-cholesterol and triglyceride levels would 
outweigh the increase in LDL-cholesterol
 155
. However, trials on high carbohydrate, reduced-
fat diets used in conjunction with lifestyle modifications, showed long-term maintenance of 
the weight lost and lowered the risk of developing type 2 diabetes
 152
. The meta-analysis study 
also examined the adherence level and it was found that both groups had a substantial dropout 
rate after 1 year, between 31% and 48% in the low-carbohydrate group and between 37% and 
50% in low-fat group. As was shown in a one year trial investigating four diets, namely, 
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Atkins (a very low carbohydrate diet), Zone (a moderately low carbohydrate diet), Weight 
Watchers (a moderately low fat diet) and Ornish (a very low fat diet), the success of a weight-
loss diet is associated more with the subject’s adherence to the diet than the macronutrient 
distribution of that particular diet
 157
. 
A review article on low-carbohydrate diets found that weight loss is predicted by energy 
intake, diet duration and baseline weight, but not by carbohydrate content
 151
. This is probably 
because it is not palatable, nor possible, to consume such a large amount of protein and fat 
constantly in real life. As a result, one consumes less energy than usual. Common short-term 
side effects include constipation, fatigue, halitosis, headache, thirst, polyuria and nausea
 151
. It 
is also easy to mislead the general public towards a poor perception of carbohydrates with 
common terms such as “carbohydrates make you fat”. Although it is not the main objective of 
this study to examine the popular dieting methods of South Africans, this finding may suggest 
a poor understanding of healthy dieting guidelines.   
4.6 Attrition rate 
At the start of the study, a total of 110 subjects were recruited, however only 87 subjects 
completed the trial. The dropout rate of 20.9% in this study is similar to the 16% of another 
study by Coffey et al.
 139
, which had a similar methodology, but utilised other ingredients and 
ran for 12 weeks. Both studies were randomized, placebo-controlled trials that studied the 
effect of dietary supplements on weight loss.  The majority of the dropouts were as a result of 
subjects not being able to complete the trial: 12 subjects did not complete the trial due to non-
compliance or missing tablets and 10 subjects did not return for the follow-up visit. One 
subject from the active group withdrew due to adverse events. This subject reported severe 
headache and heart palpitations. Data from a review article investigating factors associated 
with attrition rate showed that practical difficulties such as a full-time job can influence 
subjects’ ability to be compliant 158. In the South African setting specifically, the non-affluent 
population may not always have enough money for transport to return for the follow-up visit. 
Non-compliance may result from a lack of motivation or lack of confidence in their ability to 
lose weight
 158
. These factors can be attributed to previous weight-loss attempts and 
continuous failure, demotivating subjects. The high initial weight-loss goal is also 
significantly associated with a high attrition rate, since such expectations are often unrealistic 
and not met by the product. Persuasive and effective advertising can further escalate 
expectations, where subjects are made to believe quick weight loss is possible without much 
effort. Consequently, most consumers are unhappy with the outcome of the weight loss 
product, as it does not live up to the effects ‘guaranteed’ in the advertisement. The 
QUOVADIS, an observational study on the quality of life in treatment-seeking obese patients 
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demonstrated the same phenomenon, in which 25% of the dropouts were found to be to the 
result of dissatisfaction with the results
 158
. 
A high attrition rate compromises the internal validity of the study. As a result, one cannot 
accurately state that the observed result is solely due to the independent factor, as other 
confounding effects may have been involved. Such bias cannot be corrected by any form of 
analysis; therefore the results of this study should be interpreted with the attrition rate in mind
 
159
. 
4.7 Shortcomings and limitations of the study 
The sample size for this study was 87, which poses as a limitation on the findings. An 
increased sample size could have increased the significance of the findings, and allowed for 
possible adverse effects that occur infrequently. 
The other limitation of this study was that subjects with diseases of lifestyle, such as 
hypertension and diabetes, commonly associated with overweight and obesity, were excluded. 
It was necessary to exclude these potential subjects to ensure their safety, as some of the 
ingredients in Bioslim can increase cardiovascular risk. As a result, this prevented us from 
generalizing the findings to the general population who make use of dietary supplements for 
weight-loss and acquire them over-the-counter with no prescription required.  
Physical activity and diet were not closely examined in this study and served as a limitation 
on the finding. The study’s main objective was to investigate as closely as possible the 
general consumers’ behaviour after purchasing over-the-counter weight-loss products, 
therefore no dietary or physical exercise intervention could be included.  
Lastly, the duration of this study was one month. This study time may have been too short to 
detect side effects associated with the long term usage of Bioslim, or to observe more possible 
weight loss amongst subjects in the Active group. However, the short duration of this study 
coincides with Bioslim’s claim that it is effective after only one month. 
4.8 Conclusions 
There was no significant difference in anthropometric changes found between the active and 
placebo group. From the study result, it is concluded that in the short term, Bioslim is not an 
effective weight loss supplement. This finding is congruent with studies on other dietary 
supplement products for weight loss purposes, where none was found to be effective as a 
weight loss supplement
 131, 132, 133
. 
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However, this study has shown that Bioslim may promote fat mass loss during exercise, as 
only the active group showed a correlation between fat mass loss and the time spent on 
exercising. The actual clinical benefit of this is uncertain however, as none of the subjects in 
this study lost a significant amount of fat mass after taking Bioslim for a period of one month. 
In contrast to the results found in this study, the majority of the subjects showed great 
confidence in the efficacy of Bioslim, specifically in the group that received Bioslim branded 
products specifically. Marketing, inclusive of patient testimonials, product packaging and 
advertisements was found to be the main reason for boosting subjects’ confidence in the 
efficacy of the product. Interestingly, those who showed great confidence in the product did 
not change their lifestyle choices to promote weight loss, ignoring the package assertion 
“Only effective when used in conjunction with a kilojoule-controlled diet and moderate 
exercise”. This behaviour could be explained by influential adverts that suggest that weight 
loss is easy and effortless with Bioslim, and thus dietary changes or exercise are not 
compulsory. 
The safety of Bioslim is still a concern, as one subject in the active group withdrew from the 
study due to heart palpitations. Subjects with hypertension were excluded from this study; 
there is no such restriction in the actual market for Bioslim. There are no warning signs or 
indications that suggest possible danger to the consumer. 
Future studies should include a larger sample size to increase the statistical power of the 
results to detect possible side effects of using dietary supplements. 
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Chapter 5 
Summary, Conclusions and Recommendations 
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5.1 Summary 
It is estimated that 1.3 billion people worldwide are either overweight or obese, which makes 
it a global epidemic
 4
. In South Africa, the problem is further amplified by the double burden 
of under-nutrition and chronic diseases of lifestyle. The overall prevalence of overweight and 
obesity is relatively high compared to other African countries, with more than 29% of men 
and 56% of women in South Africa being classified as overweight or obese
 6
. This poses a 
serious risk of mortality, as WHO lists obesity as one of the 10 leading risk factors for 
mortality. It further increases the risk of a number of major chronic diseases including 
hypertension, type 2 diabetes
 10
 and cancer
 16
. 
An effective weight-loss method is lifestyle change, by increasing physical activity and 
lowering energy intake. These lifestyle changes are tough to carry out and difficult to 
maintain, resulting in a soaring increase in searches for easy weight-loss aids
 42
. Dietary 
supplements are one of the many products which exploit the eagerness of consumers to find 
an effortless weight-loss solution. They are easily accessible as they require no prescription 
and are heavily marketed to suggest that weight loss is achievable without exercise or diet. 
Bioslim, the dietary supplement tested in this study, is one such product. The results of this 
study show that Bioslim is an ineffective weight-loss aid, matching similar, previous studies 
on weight-loss dietary supplements
 131, 132, 133
. Although a significant correlation was found 
between time spent on exercising and fat mass loss in the group receiving Bioslim, and not in 
the placebo group, it is concluded that this result is inadequate to indicate clinical benefit. 
One of the misconceptions consumers have when using dietary supplements, is that they are 
considered safe because they are made from “natural” ingredients and thus cannot be harmful      
136
. However, various studies have shown that some of these herbal ingredients can be unsafe
 
88
. Ephedra, which was once a popular ingredient in weight-loss supplements is now banned 
due to its cardiovascular risk and various adverse events reported
 72
. 
Currently in South Africa, dietary supplements are not regulated by the MCC. This means 
that no clinical trials are required to ensure the efficacy or the safety of the supplements 
before they are made available to the general consumer. The hypothesis that the product has 
no effect on weight-loss was substantiated. This study emphasizes the importance of a 
placebo-controlled study to test the efficacy of a weight-loss supplement. 
The hypothesis that advertising may increase the result of a placebo response was not 
substantiated. 
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5.2 Conclusions 
It is concluded that Bioslim is an ineffective weight-loss supplement. Subjects receiving 
active pills evidenced no significant beneficial changes in weight, waist circumference or 
body composition. Although, more than half of the subjects attempted dieting and more 
exercise, it was inadequate to make an impact on weight loss. Advertising and claims made 
on Bioslim packaging did not increase the placebo effect and made no difference to weight 
loss. Television and magazine advertising for this product had ceased for a long period before 
the commencement of the study and this may have had an influence on the result. 
Although there was no difference in adverse events reported by the active or placebo group, 
one subject from the active group withdrew from the study complaining of severe headaches 
and heart palpitations. 
This study emphasizes the need for better regulation of dietary supplements for their efficacy 
and safety. 
5.3 Recommendations 
This study serves as a seed study in the hope of motivating other studies related to the use of 
dietary supplements. To the author’s knowledge, there have been no other studies conducted 
in South Africa regarding dietary supplements of any kind. This highlights the need for more 
research in this area, in South Africa particularly, since herbal medicine is a popular 
alternative treatment for various ailments including HIV. 
It is recommended that future studies include a larger study population to strengthen the 
study’s results. In addition, they should include laboratory analysis of the contents of the 
dietary supplement, to compare them to the label and to check the product quality. 
A retest of the hypothesis that advertising has a considerable effect on weight-loss in a 
placebo group, by utilising a product at the peak of its advertising campaign is also 
recommended.  
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Appendix 1: Advertisement in local newspaper 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Would you like to participate in a weight-loss trial to investigate the 
effectiveness of a popular weight-loss drug? 
 
 
You would be assigned to one of the 4 treatment groups, receiving 
weight-loss supplements for a period of one month. 
 
 
 
If interested in participating please contact 
Tina at 0726106929 
for more information. 
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Appendix 2: Consent Form  
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
TITLE OF THE RESEARCH PROJECT: 
Double blinded, placebo-controlled, randomised prospective intervention trial; to investigate the 
effectiveness of Bioslim in weight-loss and the influence of branding and advertising on the placebo 
response.  
 
 
REFERENCE NUMBER: 
 
PRINCIPAL INVESTIGATOR: 
Tzu-Ting Lee 
 
ADDRESS: 
Human Nutrition, University of Stellenbosch. PO Box 19063. Tygerberg 7505 
 
CONTACT NUMBER: 
0726106929 
 
You are being invited to take part in a research project.  Please take some time to read the information 
presented here, which will explain the details of this project.  Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand.  It is very important that you 
are fully satisfied that you clearly understand what this research entails and how you could be involved.  
Also, your participation is entirely voluntary and you are free to decline to participate.  If you say no, 
this will not affect you negatively in any way whatsoever.  You are also free to withdraw from the 
study at any point, even if you do agree to take part. 
 
This study has been approved by the Committee for Human Research at Stellenbosch University 
and will be conducted according to the ethical guidelines and principles of the international Declaration 
of Helsinki 2005 , South African Guidelines for Good Clinical Practice and the Medical Research 
Council (MRC) Ethical Guidelines for Research. 
 
 
What is this research study all about? 
 
This project will take place in the Western Cape region, where a total of 120 subjects will be recruited. 
The aim of the project is to look at the effectiveness of Bioslim in weight-loss and the influence of 
branding on consumers. 
 
You will be randomly assigned to one of the four groups where you would require taking the assigned 
drugs for a period of one month. There is an equal chance of you receiving products that do not contain 
the active ingredients of Bioslim (not real Bioslim) or active (real Bioslim). Neither you nor the 
principle investigator will know which drug you on until final analysis of the data is done. 
Furthermore, you may or may not experience any weight loss while participating in this study.   
 
Before you start taking the assigned product, you will be weighed and your mid arm circumference, 
triceps, biceps, supra ileal, subscapular skinfolds and your waist circumference will be measured. 
These measurements will not cause any pain or discomfort. At the end of the one-month trial, we will 
repeat these measurements on you again. 
 
 
Why have you been invited to participate? 
You have been invited to participate in this study because of your interest in weight loss supplements 
and do not possess qualities that may influence you negatively if you participate. 
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What will your responsibilities be? 
It is your responsibility to ensure that you attend all your appointments made with the investigator. And 
to take the products as if you would if you had brought them from the shops yourself. 
 
 
Will you benefit from taking part in this research? 
There are no personal benefits here. But the results of this study may be useful for future consumers 
when considering usage of weight loss supplements. 
 
 
Are there any risks involved in your taking part in this research? 
There are no known risks involved in participating in this study according to the manufacturers of the 
active ingredient. If you think that a side effect has occur during the taking of these tablets or during 
this study, please report this to the primary investigator. 
 
But do not participate if you are allergic to Aspirin or if you are pregnant, breastfeeding, diabetes or on 
any heart medication.  
 
 
Who will have access to your medical records? 
The information that is collected will be treated as confidential information; if the results are published 
all identities of the participants will remain anonymous. 
 
 
Will you be paid to take part in this study and are there any costs involved? 
 
There is no remuneration for participating in this study.  
 
 
Is there anything else that you should know or do? 
You should inform your family practitioner or usual doctor that you are taking part in a research study. 
You can contact the study primary investigator – Tina Lee, if there is any queries during the 
participation of this research at 0726106929. 
or 
You can contact the Committee for Human Research at 021-938 9207 if you have any concerns or 
complaints that have not been adequately addressed by your study investigator. 
You will receive a copy of this information and consent form for your own records. 
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Appendix 3: Questionnaire 
 
Questionnaire Participant ID:                                          Date:  
1) Have you used any weight-loss product before joining this study? Yes No 
If yes, continue by answering question 1a, 1b,1c. If no, continue by answering question 2. 
1a) Please name the product(s), duration of use and date of usage: 
1b) Did you experience any negative side effects? (Such as hunger, 
abdominal pain, headache, thirst, discolouring of urine, fatigue, 
nausea, diarrhoea or heart palpitation) 
Yes No 
If yes, what were they: 
1c) The outcome was Satisfactory None satisfactory 
If satisfactory, how so: 
If unsatisfactory, how so: 
The following questions apply to this study 
2) The outcome was Satisfactory None satisfactory 
If satisfactory, how so: 
If unsatisfactory, how so: 
3) Did you exercise Yes No 
If yes, continue by answering question 3a and 3b. If no, continue by answering question 4. 
3a) How many days per week 
(please choose one) 
1 2 3 4 5 6 7 
3b) How long each session and what type of exercise: 
4) Did you change the way you eat while participating in this 
study?  
       Yes 
        
No 
4b) If yes, how: 
5) Did you follow a energy restricted diet Yes No 
If yes, continue by answering question 5a. If no, continue by answering question 6. 
5a) Did you follow the diet on the package insert? Yes No 
If yes, then was it: 
Most of the time, with 1 or 2 
days missed  
Tried, but failed to 
continue  
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6) Did you experience any discomfort or negative side effect while 
participating in this study? (Such as hunger, abdominal pain, 
headache, thirst, discoloring of urine, fatigue, nausea, diarrohea 
or heart palpitation.) 
Yes No 
If yes, continue by answering question 6a. If no, continue by answering question 7. 
6a). What was the adverse event? 
7) Have you missed taking any pills Yes No 
If yes, how many days:  
8) Did you believe this product would work for you Yes No 
8a) If yes, why 
9) Have you ever encounter Bioslim advertisements before? Yes No 
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